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It is now a standard practice in the study of complex disease to perform many high-throughput  
-omic experiments (genome wide SNP, copy number, mRNA and miRNA expression) on the 
same set of patient samples. These multi-modal data should allow researchers to form a more 
complete, systems-level picture of a sample, but this is only possible if they have a suitable 
model for integrating the data. Due to the variety of data modalities and possible combinations of 
data, general, flexible integration methods that will be widely applicable in many settings are 
desirable. In this dissertation I will present my work using graphical models for de novo structure 
learning of both undirected and directed sparse graphs over a mixture of Gaussian and 
categorical variables. Using synthetic and biological data I will show that these models are useful 
for both variable selection and inference. Selecting the regularization parameters is an important 
challenge for these models so I will also cover stability based methods for efficiently setting 
these parameters, and for controlling the false discovery rate of edge predictions. I will also show 
results from a biological application to data from metastatic melanoma patients where our 
methods identified a PARP1 slice site variant that is predictive of response to chemotherapy. 
Finally, I present work incorporating miRNA into a pathway based graphical model called 
PARADIGM. This extension of the model allows us to study patient-specific changes in miRNA 
induced silencing in cancer. 
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1.0  INTRODUCTION 
In the Era of Big Data researchers are presented with many new problems that standard statistical 
methods and models are not equipped to handle. The statistics and machine learning literature is 
ripe with novel approaches that may fit the needs of a given biological problem, but there are 
often hurdles to adapt these approaches to a given problem, including parameter selection, 
computational requirements, and normalization issues. This dissertation sits at the intersection of 
statistics and biology and therefore I will endeavor to present methods and models that are 
adaptable to a wide variety of biological problems and systems while presenting potential users 
with guidelines for the use of these tools.  
Integrative analysis of data of different modalities and different sources is a common task 
in biomedical research. In particular, finding relationships between continuous and categorical 
variables with several levels can be challenging as it often requires non-intuitive methods such as 
conversion of categorical variables to binary dummy variables. We explore this mixed variable 
type setting in depth in this dissertation, and present strategies for learning both undirected and 
directed graphical models over these data. 
Using directed modes to predict causal relationships between variables is especially 
desirable in the study of human disease, as we would like to be able to treat the aberrant biology 
that is causing the disease rather then the downstream variables that are merely side effects of the 
change in the causal variable. We focus on the difficult problem of predicting causality from 
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observational data here which is common for exploratory studies in modern biology. 
Relationships predicted by our models are candidates for validation in directed laboratory 
experiments. Recently, high-throughput knockdown experiments have been performed to study 
causal relationships at genomic scale. While this data is invaluable for causal modeling in 
biology, these types of experiments are still expensive and relatively new, so we aim to be 
widely applicable to the enormous body of observational data currently available. We anticipate 
that as these large-scale perturbation studies become more wide-spread they will be a valuable 
source of data for both validation of and integration with causal search algorithms. 
In this dissertation I will present several tools for integrative analysis of multiple types of 
data. Chapters 2 and 3 focus on finding networks of interactions between these multimodal data. 
Although there are large-scale databases of known interactions between DNA, RNA, protein and 
other epigenetic factors, we initially focus on de novo methods which search for interactions 
without any prior knowledge as a proof of concept, to allow for validation with prior knowledge 
and to allow for integration of variables that do not have good coverage in the literature such as 
clinical tests, patient traits, and newer biological data types. Chapter 2, adapted from an article 
we recently published (Sedgewick et al. 2016), presents work on learning undirected networks 
over mixed variable types. Chapter 3 uses the methods from chapter 2 as a starting point for 
directed causal search algorithms. In chapter 4 (adapted from (Abecassis et al. 2015)) I present 
an in depth look at a successful application of these network search algorithms to a cohort of 
patients with metastatic melanoma where we were able to identify a single nucleotide 
polymorphism (SNP) that predicts how patients will respond to treatment. Finally, in chapter 5 I 
tackle the problem of integrative network analysis from the other direction by extending 
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PARADIGM, an algorithm that depends heavily on prior knowledge of biological pathways, to 
handle a new type of data, miRNA. 
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2.0  UNDIRECTED GRAPHICAL MODELS WITH MIXED VARIABLES 
Mixed graphical models (MGMs) are graphical models learned over a combination of continuous 
and discrete variables. These models provide both a network structure and a parameterized joint 
probability density over these heterogeneous variables, which are common in biomedical 
datasets. The network structure reveals the direct associations between variables and the joint 
probability density allows one to ask arbitrary probabilistic questions on the data. This 
information can be used for feature selection, classification and other important tasks. We 
studied the properties of MGM learning and applications of MGMs to high-dimensional data 
(biological and simulated). Our results show that MGMs reliably uncover the underlying 
undirected graph structure, and, when used for classification, their performance is comparable to 
popular univariate methods (lasso regression and support vector machines). We also show that 
imposing separate sparsity penalties for edges connecting different types of variables 
significantly improves edge recovery performance. To choose these sparsity parameters, we 
propose an efficient model selection method based on an existing method, stability approach to 
regularization selection (StARS). We call this approach Stable Edge-specific Penalty Selection 
(StEPS). MGMs produced by StEPS outperform models selected using standard techniques 
(including AIC, BIC and cross-validation) in edge recovery. In addition, our method uses a 
heuristic search that is linear in size of the sparsity value search space as opposed to the cubic 
grid search required by other model selection methods. An MGM learned over mRNA 
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expression and clinical data from the Lung Genomics Research Consortium correctly recovered 
connections between the diagnosis of obstructive or interstitial lung disease, two diagnostic 
breathing tests, and cigarette smoking history. Our model also suggested biologically relevant 
mRNA markers that are linked to these three clinical variables. 
2.1 BACKGROUND 
Integrating biomedical datasets from different data streams (e.g., -omics, clinical) and of 
different types (continuous, discrete) is of utmost importance and has become an analysis 
bottleneck in biomedical research. Ideally, one would like to be able to uncover all direct 
associations between variables and/or perform feature selection and classification tasks using all 
data. The first task can reveal disease mechanisms and the second can be used to select variables 
characteristic of disease status, therapy outcome or any other variable of clinical importance. 
Graphical models have been used in the past for both of these tasks, but they are often limited to 
datasets with discrete-only or continuous-only variables. Traditional univariate approaches for 
feature selection exist as well, but they also often operate on a single data type. In addition, due 
to the high dimensionality and co-linearity of biological data, markers selected by these standard 
feature selection algorithms can be unstable and lack biological relevance (Abeel et al. 2010), a 
problem that has recently been addressed directly (Huang et al. 2014). Many existing models that 
do integrate different data types make heavy use of prior knowledge (Sedgewick et al. 2013; 
Wang et al. 2013) and as such are not easily extendable to clinical and other data that are not 
well studied. As a result, although numerous biomedical data sets exist with genomic, 
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transcriptomic, epigenetic and phenotypic data for each sample, a general framework for 
integrative analysis of these heterogeneous data is lacking.  
In this chapter, we study several strategies for learning the structure of graphical models 
over mixed data types (discrete and continuous) to produce statistically and biologically 
meaningful predictive models. We measure the performance of these strategies in synthetic data 
(via true edge recovery) and biological data (via functional enrichment and performance on 
classification tasks). 
The major contributions of this work are threefold. First, we apply an MGM, proposed by 
Lee and Hastie (Lee and Hastie 2013), to simulated and biological datasets. These datasets have 
higher dimensionality and are derived from more complicated network structures than datasets 
used in previous work with this model. Second, we propose the use of a separate sparsity penalty 
for each edge type in the MGM, which significantly improves performance. Third, to assist with 
setting the sparsity parameters we use a heuristic search, StEPS, based on an existing model 
selection method (StARS) (Liu et al. 2010), that outperforms standard methods.  
2.1.1 Prior work 
Graphical models are a natural tool for decoding the complex structure of heterogeneous data 
and allow for integration of many data types. They learn a network of statistical dependencies 
subject to a joint probability distribution over the data. Mixed graphical models (MGMs) are 
graphical models learned over a mixture of continuous and discrete features.  
A fully specified conditional Gaussian MGM, as characterized by Lauritzen & Wermuth 
(Lauritzen and Wermuth 1989), would require different continuous distribution parameters for 
every possible setting of the discrete variables. Restricting ourselves to “homogeneous” models, 
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which use a common covariance matrix for continuous variables independent of the discrete 
variable values, is therefore necessary to avoid trying to learn a parameter space that is 
exponential in the number of variables. Similar to pairwise Markov Random Fields over only 
discrete variables, the main hurdle to the calculation of likelihood in MGMs is calculation of the 
partition function. This computation is intractable with a large number of discrete variables 
because it requires summing over all possible discrete variable settings. Two approaches to get 
around this partition function calculation are: (1) learn separate regressions of each variable 
given all of the others (Fellinghauer and Bühlmann 2011; Chen et al. 2014; Yang et al. 2014), 
and (2) maximize a tractable pseudolikelihood function instead of the actual likelihood (Lee and 
Hastie 2013). 
Performing separate regressions is a common approach to the MGM learning problem. 
This class of methods learns a conditional distribution for each node given the rest. Examples of 
this strategy include estimation of the sparse inverse covariance matrix of a multivariate 
Gaussian by Meinshausen and Bühlmann (Meinshausen and Buehlmann 2006), and estimation of 
mixed variable networks via random forests (Fellinghauer and Bühlmann 2011) or exponential 
families (Chen et al. 2014; Yang et al. 2014). Alternatively, the pseudolikelihood, proposed by 
Besag (Besag 1975), is a consistent estimator of the likelihood, and is defined as the product of 
the conditional distributions of each node given the rest. Both of these approaches thus avoid 
calculation of the partition function for the joint distribution by substituting the conditional 
distributions of each node into the optimization problem. Separate regressions offer flexibility 
and are easily parallelized, but in both the continuous (Friedman et al. 2008) and mixed cases 
(Lee and Hastie 2013) estimating the parameters by maximizing the likelihood or 
pseudolikelihood, respectively, has the advantage of better empirical performance. Because of 
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this we chose the focus our efforts on the MGM learning approach via pseudolikelihood, as 
proposed in Lee and Hastie (Lee and Hastie 2013).  
Although Lee and Hastie do not test their algorithm on high-dimensional data, we find 
that their model is well suited for high-dimensional learning due to their inclusion of a sparsity 
penalty on the parameters. An important issue that we ran into in our experiments was that the 
model would often select too many continuous-continuous edges and too few edges involving 
discrete variables. This is likely a combination of the phenomenon observed in (Chen et al. 2014) 
where linear regressions have better edge prediction performance than logistic regression 
between the same nodes and the fact that Lee and Hastie use the same sparsity penalty on all 
edges regardless of the type(s) of nodes they connect. Lee and Hastie use a weighting scheme to 
take into account discrete variables with differing numbers of categories, but this does not solve 
this problem. Therefore, in this paper we introduce a new regularization method for the Lee and 
Hastie’s model that uses a different penalty for each type of edge: continuous-continuous, 
continuous-discrete, and discrete-discrete. In addition, because this approach creates more 
parameters for the user to set, we present an edge stability based method for selecting the three 
sparsity parameters. We call the combination of using separate sparsity penalties with our 
heuristic search Stable Edge-specific Penalty Selection (StEPS). 
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2.2 METHODS 
2.2.1 Mixed Graphical Models 
Lee and Hastie (Lee and Hastie 2013) parameterize a mixed graphical model over p Gaussian 
variables, x, and q categorical variables, y, as a pairwise Markov Random Field. Here we briefly 
summarize their model: 













In this model !!" represents the interaction between two continuous variables, !! and !!, !!" !!  is a vector of parameters that correspond to the interaction between the continuous 
variable !! and the categorical variable !! indexed by the levels (i.e. categories) of the variable !!, and !!"(!! ,!!), is a matrix of parameters indexed by the levels of the categorical variables !!, and !!. In the continuous only case, this model reduces to a multivariate Gaussian model 
where the !!" parameters are entries in the precision matrix. In the categorical only case, this 
model is the popular pairwise Markov random field with potentials given !!"(!! ,!!); and it 
could parameterize an Ising model as in the binary-only case, for example. Thus the model 
serves as a generalization of two popular uni-modal models to the multi-modal regime. 
In order to avoid the computational expense of calculating the partition function of this 
model, Lee and Hastie optimize the negative log pseudolikelihood, which is:  




where !\! is short hand for the set of all !! where ! ≠ !. To ensure a sparse model, ! is 
minimized with respect to a sparsity penalty, !: 
minimize! ! Θ +  ! !!"!!!  +  !!" !!,! +  !!" !!!!  
where Θ is a shorthand for all of the model parameters. The parameter matrices ! and ! are 
symmetric, so only half of each matrix is penalized. Lee and Hastie use an accelerated proximal 
gradient method to solve this optimization problem. 
A standard way of handling a categorical variable with L levels is to convert the variable 
to L-1 indicator variables where the last level is encoded by setting all indicators to zero, this is 
necessary to ensure the linear independence of variables in the regression problem. This can lead 
to some ambiguity about the choice of the last level and how to interpret the regression 
coefficients. In contrast, Lee and Hastie’s MGM approach uses L indicator variables (i.e. the 
elements of !!" !!  and !!"(!! ,!!)) to improve interpretability of the model, and enforces a 
group penalty to ensure the indicator coefficients sum to zero. 
To perform our experiments we adapted the Matlab code provided by Lee and Hastie 
(available at http://web.stanford.edu/~jdl17/learningmgm.html). 
2.2.2 Separate Sparsity Penalties 
Our main modification to the Lee and Hastie model itself is that we use different sparsity 
penalties for the three edge types: edges connecting two continuous nodes (cc), edges connecting 
a continuous and discrete node (cd) and edges connecting two discrete nodes (dd). With these 
penalties, the new optimization problem becomes: 
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minimize! ! Θ +  !!! !!"!!!  +  !!" !!" !!,! +  !!! !!" !!!!  
2.2.3 Methods for Model Selection 
K-fold cross-validation (CV) (Efron 1982) splits the data into K subsets and holds each set out 
once for validation while training on the rest. We use K=5 and average the negative log-
pseudolikelihood of the test sets given the trained models.  
The Akaike information criterion (AIC) (Akaike 1998) and Bayes information criterion 
(BIC) (Schwarz 1978) are model selection methods that optimize the likelihood of a model based 
on a penalty on the size of the model represented by degrees of freedom. To calculate the AIC 
and BIC, we substitute the pseudolikelihood for the likelihood and we define the degrees of 
freedom of the learned network as follows.  
In the standard lasso problem, the degrees of freedom is simply the number of non-zero 
regression coefficients (Zou et al. 2007). So, in the continuous case, the degrees of freedom of a 
graphical lasso model is the number of edges in the learned network. In the mixed case, edges 
incident to discrete variables have additional coefficients corresponding to each level of the 
variable. Lee and Hastie’s MGM uses group penalties on the edge vectors, !, and matrices, !, to 
ensure that all dimensions sum to zero. So, in the model, an edge between two continuous 
variables adds one degree of freedom, and edge between a continuous variable and a categorical 
variable with L levels adds L-1 degrees of freedom, and an edge between two discrete variables 
with Li and Lj levels adds (Li – 1)(Lj  - 1) degrees of freedom.  
We compare these model selection methods to an oracle selection method. For the oracle 
model, we select the sparsity parameters that minimize the number of false positives and false 
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negatives between the estimated graph and the true graph. While we do not know the true graph 
in practice and none of the other methods use the true graph, this method shows us the best 
possible model selection performance under our experimental conditions. 
AIC, BIC, and CV all require calculating the pseudolikelihood from a learned model so 
to optimize over separate sparsity penalties for each edge type, we perform a cubic grid search of !!!, !!", and !!! over . 64, .32, .16, .08, .04 . 
2.2.4 Stability for Model Selection 
Here we briefly present the StARS procedure (Liu et al. 2010) reformulated in terms of ! rather 
than ! =  1 ! as was originally described. Given a dataset with n samples, StARS draws N 
subsamples of size b without replacement from the set of !!  possible subsamples. An MGM 
network is learned for each subsample over a user specified set of values and a single sparsity 
parameter, !. The adjacency matrices from these learned models are used to calculate , !!"(!), 
the fraction of subsample networks that predict an edge from node s to node t. Using this value 
we can then calculate edge instability, !!"(!) = 2!!"(!)(1−  !!" ! ), which is the empirical 
probability of any two subsample graphs disagreeing on each possible edge at each value of !. 
Liu et al define total instability of the graph, !(!), as the average of !!"(!) over all edges: !(!) =  !!"(!)!!!!!!! . Very low values of ! will result in very dense but stable graph, which is not 
desirable. To avoid this, StARS monotonizes the instability: !(!) = sup!!! !(!) and selects ! = inf ! ∶  ! ! ≤ !  where ! is a user defined threshold (called ! in (Liu et al. 2010)). In 
other words, starting with a large value of ! that produces an empty graph, we reduce ! until the 
total instability hits the given threshold.  
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2.2.5 Stable Edge-specific Penalty Selection (StEPS) 
We modified the StARS procedure to accommodate selection of separate ! for each edge type. 
We now define the total instability over each edge type instead of the entire graph: !!!(!) = !!"(!)!! !! , !!"(!) =  !!"!" (!)!" , !!!(!) =  !!"(!)!! !! . Given these separate estimates of total 
instability, we then perform the rest of the StARS algorithm for !!!, !!", and !!! independently. 
This approach does not require any additional model learning, the only extra computations in this 
approach compared to the standard, single penalty StARS are the additional averages, which are 
trivial to calculate. Because the subsample network learning uses the single penalty MGM, this 
procedure is linear in the size of the parameter search space. Based on the suggestions in (Liu et 
al. 2010), and the default parameters in the R implementation of StARS (Zhao et al. 2012), we 
use ! = 20, ! = 10 !, and ! =  .05. 
2.2.6 Simulated Network Data 
We generated 20 scale-free networks of 100 variables each, based on the framework of Bollobás 
et al (Bollobás et al. 2003) but ignoring edge direction. So, given a number of nodes to connect, 
we start with an edge between two nodes and the rest of the nodes unconnected, we iteratively 
add edges until all nodes are connected. At each edge addition, we connect two non-zero degree 
nodes with probability .3; and we connect a node i with degree 0 to a node j with non-zero 
degree with probability 0.7. In each case, the non-zero degree nodes are selected randomly with 
probability proportional to their degree: !"#$""(!)!"#$""(!)! ∈! . 
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For each network we simulated two datasets of 500 samples with 50 continuous and 50 
categorical variables. Each categorical variable had 4 levels. The parameters in one dataset were 
set so that discrete-continuous and discrete-discrete edges had approximately linear interactions, 
while the other dataset did not have this constraint. Each edge, from node s to node t is given a 
weight, wst, drawn uniformly from [.5, .8]. For continuous-continuous edges we chose a sign 
with even probability and set !!" =  !!" or !!" =  −!!". To ensure the ! matrix is positive 
definite, we set the diagonal elements the largest value of the sum of the absolute value of the 
edge weights over each node. For continuous-discrete edges, in the linear dataset we set !!" = −!,−.5!, .5!,!  (so if the levels of a discrete variable are coded as adjacent integers it 
can be treated as a continuous variable and will have a linear relationship with neighboring 
nodes) and in the non-linear data we set !!" = !"#$ −!,−.5!, .5!,! , where perm is a 
random permutation of the elements in the vector. For discrete-discrete edges we set the diagonal 
of !!" !! ,!!  to wst and the rest to -wst, while in the non-linear data we randomly set one 
parameter in each column and row to wst and the rest to -wst.. 
2.2.7 Lung Chronic Disease Data 
The Lung Genomics Research Consortium (LGRC) contains multiple genomic datasets and 
clinical variables for two chronic lung diseases: chronic obstructive pulmonary disease (COPD) 
and interstitial lung disease (IDL). We used two data types from LGRC: gene expression profiles 
(15,261 probes) and clinical data for 457 patients (COPD N=215; ILD N=242). To expedite the 
execution time and avoid sample size problems, we only used the 530 most variant expression 
probes and 8 clinical variables: age, height, weight, forced expiratory volume in one second 
(FEV1), forced vital capacity (FVC), gender, cigarette history, and diagnosis (COPD or ILD). 
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Age, height, weight and the spirometry variables (FEV1 and FVC) were divided into tertiles. 
Diagnosis was used for classification experiments.  
2.2.8 Graph Estimation Performance 
Non-zero MGM edge parameters correspond to a prediction of the presence of that edge. For 
edges with multiple parameters, (i.e. !!" !!  and !!" !! ,!! ) if any of the parameters are non-
zero we predict the edge is present. We use accuracy, precision and recall to evaluate edge 
recovery in our predicted graphs: precision is the ratio of true edge predictions to all edge 
predictions; recall is the ratio of true edge predictions to all edges in the true graph; accuracy is 
the ratio of true predictions to all predictions (in this case true prediction includes the correct 
predictions of the presence or absence of an edge); and the F1 score is the harmonic mean of 
precision and recall. In addition we consider the Matthews’ correlation coefficient (MCC) 
(Matthews 1975) which provides a correlation between the presence of edges in the true and 
predicted graphs. MCC is formulation of Pearson’s correlation for two binary variables so values 
of 1 correspond to perfect agreement between the variables, -1 to all disagreements, and 0 to 
random guessing. This measure is robust to unbalanced nature of the problem where in the true, 
sparse graph edge absence is much more frequent than edge presence. 
2.2.9 Functional Enrichment and Classification 
For evaluation of the performance of various MGMs and other models on real data we used 
functional enrichment analysis of external databases and classification analysis over specific 
variables in the network, including disease diagnosis (for clinical datasets).  
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Gene annotations were retrieved from the Gene Ontology (GO) database (Consortium 
2015) and we used the hypergeometric test to determine if sets of selected genes were 
overrepresented for any of these annotations (i.e. more occurrences of a given annotation were 
observed than we would expect from randomly selected genes). 
Given the parameters learned from training data, !!"#$%, we make predictions on any 
categorical variable, !!"#$%!, in a testing dataset given the rest of the variables by selecting the 
category minimizes the negative log pseudolikelihood of the test data given the trained model:  !!"#$%! = !"#$%&!!"#$%!  ! (!!"#$%; !!"#! ,!!"#!\!"#$%! ,!!"#$%! = !!"#$%!) 
We use this approach to predict lung disease diagnosis in a test dataset with an MGM 
trained with a training dataset.  
We used 8-fold cross validation to determine the optimal classification settings of ! for 
MGM and Lasso, and which kernel to use for support vector machines (SVMs). We used the 




2.3.1 Separate Sparsities versus Single Sparsity Parameter 
 
Figure 2.1 Example adjacency matrices predicted by an MGM, with sparsity selected using the oracle. a. Single 
sparsity penalty ! =  .19 b. Split sparsity penalties !!! =  .64, !!" =  .19, !!! =  .13 
 
We applied Lee and Hastie’s method for learning an MGM to datasets simulated from a scale-
free network. Initial experiments found that using a single sparsity penalty for all edge types 
produced many false positive continuous-continuous edge predictions, while missing many true 
discrete-discrete edges.  We first present an example of this behavior on a single dataset of 500 
samples over 50 four-level discrete variables and 50 continuous variables generated from a scale 
free network structure. Figure 2.1a shows the adjacency predictions of the learned MGM 
compared to the true graph using a ! selected by the oracle to minimize the number of edges 
present in one graph but not the other. This observation leads us to introduce separate sparsity 

























separate sparsity penalties for each edge type. For the sparsity parameters, the oracle searched 
over a range of 13 values evenly spaced on a log scale from .08 to .64.  
Figure 2.2 shows the Matthews correlation of the edge predictions over the range of 
sparsity parameters, both overall and separated by edge type. For this example dataset, edge 
recovery of discrete-discrete edges had the highest MCC at ! =  .13 while correlation of 
recovery of continuous-discrete edges was maximized at ! =  .19 and continuous-continuous 
edges at ! =  .64. 
 
Figure 2.2 Matthews correlation between edge predictions and the true graph versus sparsity for the example dataset 
from Fig. 2.1. Calculated for each edge type, cc for continuous-continuous, cd for continuous-discrete, dd for 
discrete-discrete, and over all edge predictions. 
 
Selecting an optimal value for a single ! can be challenging, and the addition of two more 
sparsity parameters made it necessary to develop an efficient selection strategy. Other methods 
with multiple sparsity parameters search over a grid of models learned on all possible 
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combinations of the parameters (Zhang and Kim 2014), but for our model the complexity of this 
selection would be cubic in the number of parameter values tested. Many model selection 
methods rely on calculating some likelihood over the training data, and it is not clear how to 
divide up this calculation by edge type. We do expect the presence of edges to remain relatively 
constant for a given edge sparsity parameter setting, so we extended a recent subsampling 
technique for model selection, StARS (Liu et al. 2010), to select three edge-type specific sparsity 
penalties by assuming independence between edge types. This assumption allows for a linear 
rather than cubic search over possible sparsity parameters. Thus, our method, StEPS, selects 
three sparsity penalties for Lee and Hastie’s MGM learning using a modified StARS approach 
for subsampling over different edge types. 
2.3.2 StEPS Outperforms Other Methods for Model Selection  
Table 2.1 Comparison of model selection methods. Mean (and standard error) of classification performance over 20 
datasets simulated from scale-free networks. The entry for the method that performs best (excluding the oracle) in 
each category is bolded. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; CV: cross-
validation; Oracle: best possible prediction performance (maximize accuracy using true graph). 
Methods Precision Recall F1-score Matthews CC Accuracy 
AIC 0.1104 (0.002) 0.9698 (0.004) 0.1982 (0.003) 0.2882 (0.003) 0.7952 (0.003) 
BIC 0.4588 (0.028) 0.8633 (0.007) 0.5890 (0.025) 0.6098 (0.022) 0.9652 (0.004) 
CV 0.1530 (0.003) 0.9694 (0.004) 0.2640 (0.005) 0.3539 (0.004) 0.8587 (0.003) 
Oracle 0.9149 (0.015) 0.7868 (0.021) 0.8397 (0.009) 0.8416 (0.008) 0.9923 (0.000) 
StARS – 1 ! 0.8988 (0.018) 0.4993 (0.010) 0.6408 (0.011) 0.6632 (0.011) 0.9854 (0.001) 
StEPS – 3 ! 0.9159 (0.014) 0.6720 (0.009) 0.7731 (0.007) 0.7787 (0.007) 0.9897 (0.000) 
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Table 2.1 Summarizes graph prediction results for MGMs trained using sparsity penalties 
chosen with different model selection procedures over the 20 simulated non-linear datasets. 
Oracle, AIC, BIC, and CV evaluated models over a three dimensional grid of all possible 
combinations of !!! , !!" , !!! ∈ . 64, .32, .16, .08, .04 . For StARS, models were trained using a 
single sparsity penalty over the same range of values, and then either a single ! was selected 
based on the average instability over all edges or !!! , !!" and !!! were selected based on the 
average instability of each edge type.  
Our results show that AIC, BIC and CV produce overly dense models in the high-
dimensional setting. Even when restricted to the single sparsity model, StARS significantly 
outperforms these traditional model selection methods. These results agree with what Liu et al 
observed in their model selection experiments with the graphical lasso (Liu et al. 2010). In 
addition, our modification of StARS with separate sparsities outperforms StARS with a single 
sparsity. Neither StARS model selection with 3 penalties nor the oracle model selection output a 
model where all three sparsities were equal in any of these experiments. Both methods always set !!! =  .16 while the other parameters were always in the set  .64, .32, .16 . These results 
confirm the effectiveness of separating the MGM sparsity penalty into three ! values.  
The original StARS procedure uses a subsampled dataset to make final edge predictions 
because the instability calculations are made on subsamples. We found, however, that in all cases 
the final edge prediction performance is higher if we use all samples compared to predictions 
from a model using a subsampled dataset. This improved performance is observed for all three 
metrics: accuracy, MCC, and F1. So, for all results presented below we used all samples to learn 
the MGM and make edge predictions with StARS selected sparsities. 
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It is important to note that because our method, StEPS, selects each sparsity parameter 
independently, it incorrectly assumes that the instability of each edge type is independent of the 
parameters of the other edge types. Without this assumption, we would have to perform stability 
experiments on all combinations of the sparsity parameters. To test if this assumption is reducing 
the edge recovery performance of StEPS, we ran StARS on the non-linear datasets using all 125 
possible settings of λ!!, λ!", λ!! ∈ . 64, .45,   .32, .23, .16 . This search space was chosen 
because all of the values selected by the Oracle or either of the other StARS methods fell in the 
set . 64, .32, .16  and additional intermediate values were needed to compare the relative 
performance of these methods. Although StARS occasionally selected values of .64 and .16 
which are on the boundary of this test range, we did not include higher or lower values because 
.32 was selected most of the time, and the cubic growth made it expensive to search over more 
than 5 penalty values. This experiment posed a new problem of how to monotonize and select 
the total instability over three dimensions rather than one. In addition, this experiment showed 
that the number of predicted edges in the graph does not always increase when one of the ! 
parameters decreases, even when the other two are held constant. We found that simply choosing 
the model with monotonized total instability closest to the user-specified ! threshold produced 
poor results. Taking into account the number of edges predicted across all subsamples for each 
parameter setting, as described below, was essential to producing usable results. 
We first looked at the total instability of the whole graph with all edge types pooled 
together, !!"" λ!!, λ!", λ!! . We monotonized this 3-dimensional matrix across each dimension: !!"" λ!!, λ!", λ!! =  sup!!!,!!",!!!!!!,!!,!!  !(!!, !!, !!) and selected the setting of λ!!, λ!", λ!! 
that produced subsampled networks with the most edges such that  !!"" λ!!, λ!", λ!! ≤ ! = .05. Surprisingly, this approach performed worse than StEPS on all measures. MCC, for 
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example, was significantly worse (mean of .845 for the heuristic versus .718 for this method, t-
test p = 1.4e-4). We found that the networks produced by this method were too dense in the 
continuous-continuous edges and too sparse in continuous-discrete edges (results not shown). 
This is the result of averaging the instability of all edge types: the selected models were too 
stable for some edge types and too unstable for other types. To fix this, we separated the 
instability as before into !!! λ!!, λ!", λ!! , !!" λ!!, λ!", λ!!  and !!! λ!!, λ!", λ!! , and 
monotonized as before. Then we choose λ!!, λ!", λ!! that produced networks with the most edges 
such that !"#(!!! λ!!, λ!", λ!! ,!!" λ!!, λ!", λ!! ,!!! λ!!, λ!", λ!! ) ≤ ! =  .05. On 17 of the 
20 datasets tested, this approach selected the same sparsity parameters as our proposed linear 
parameter search method. For the three runs where the two methods selected different 
parameters, the cubic search made better choices than the heuristic. Averaging over all runs the 
cubic search performed better than the heuristic but these results are not significant (e.g., mean 
MCC for the cubic search was .850 versus .845 for StEPS, p = 0.56). These results indicate that 
the independence assumption made by our heuristic is reasonable and that StEPS performs only 
slightly worse than a more theoretically sound cubic search while requiring much less 
computation. 
2.3.3 Comparison to SCGGM 
An important potential application of MGMs is in identifying expression quantitative trait loci 
(eQTLs) based on the predicted dependencies between single nucleotide polymorphisms (SNPs) 
and mRNA expression. The sparse conditional Gaussian graphical model (SCGGM) (Zhang and 
Kim 2014) is a method that addresses this problem specifically. Like many methods for finding 
eQTLs, the SCGGM assumes a linear relationship between the number of variant alleles and the 
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mRNA expression level. Thus, the SCGGM is not technically a mixed graphical model because 
it treats the SNP allele counts as continuous variables. Another difference is that SCGGM does 
not predict discrete-discrete edges, which is also common among methods for finding eQTLs. 
Like StEPS, SCGGM also adopts a strategy of using a separate sparsity penalty for each edge 
type. SCGGM uses cross-validation to search over a two dimensional grid of parameter values in 
order to optimize prediction of continuous values given the discrete values.  
 
Figure 2.3 Comparison of edge recovery performance of MGM and SCGGM on continuous-continuous (cc), 
continuous-discrete (cd) and both edge types. Matthews correlation is averaged over 20 simulated datasets with 
linear continuous-discrete interactions and 20 datasets  with non-linear interactions with error bars ± one standard 
error. Sparsity parameters for both methods selected by StEPS. Figure created in collaboration with Ivy Shi. 
 
First, we examined how our stability method can be used in SCGGM parameter selection 
instead of cross validation on our synthetic data and we found that StEPS resulted in 
significantly higher MCC (p < .01) for recovery of both continuous-continuous and continuous-
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discrete edge types. To perform a comparison between MGM and SCGGM edge predictions we 
used two sets of 20 mixed datasets generated from the same set of 20 scale-free networks but 
with parameters that resulted in either linear or non-linear interactions between discrete and 
continuous variables. Figure 2.3 shows the results of this experiment with StEPS selected 
sparsity parameters. As expected, MGM learning performed similarly on the linear and non-
linear datasets because it does not assume linearity. The SCGGM had similar performance on 
continuous-continuous edge recovery with both datasets, but significantly worse performance on 
continuous-discrete edge recovery in the data with non-linear cd interactions, which resulted in 
worse overall performance in that setting. 
For these tests we found that when allowing the selection of (different) edge type specific 
sparsity penalties, SCGGM chose the same penalty for the cc and cd edges in 36 out of the 40 
datasets; and StEPS chose the same penalty for the cc and cd edges in 38 out of the 40 datasets, 
but a different dd penalty in all 40 cases. 
2.3.4 Performance of MGM on Lung Disease Data 
It is difficult to evaluate the edge recovery performance of MGM in real clinical datasets since 
the ground truth (all associations between variables) is not generally known. Alternatively, we 
evaluate MGM performance indirectly, by (1) recovering the small number of interactions that 
are known, (2) using external datasets (GO categories) to see if connected genes have similar 
function, (3) performing classification on a target variable in the network (disease diagnosis).  
We applied our MGM learning approach to the LGRC biomedical data (described 
above). On this data StEPS selected the same value of !!! , !!" =  .2 for an average instability 
threshold of ! =  .05 and !!! , !!" =  .1 for ! =  .1. The selection of !!! proved more 
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problematic. Even with  ! =  .1, !!! was selected to be so high that only one edge was selected 
(FEV1-FVC). This issue is likely caused by the fact that there are only 28 possible edges 
between the 8 clinical variables, and we expect that many of these variables are connected. 
Because of this and the fact that the experiments we perform below depend more on the 
continuous-discrete edges, we set all three penalties to the same value for our parameter searches 
in this section.  
2.3.5 Recovering Known Interactions 
 
Figure 2.4 Learned sub-network of gene expression and clinical features connected to lung disease diagnosis, lung 
tests and cigarette smoking. Nodes are colored by data type, blue for gene expression, red for clinical variables. 
Edges were filtered by weight with a threshold of .05. Node size is proportional to the diagonal of the ! matrix for 
continuous variables and !!! ! for each categorical variable, y. 
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Figure 2.4 shows part of the network learned over the lung (LGRC) dataset with !!! , !!" , !!! = .1. We only show the nodes adjacent to the clinical variables most relevant for lung disease: 
diagnosis, spirometry tests and cigarette smoking. This model found a very strong connection 
between the FEV1 and FVC variables. A number of relevant gene expression variables are 
linked to diagnosis in this network. IL13 is part of the family of interleukin signaling molecules, 
which are associated with inflammatory response to tissue damage, and COPD is an 
inflammatory disease. We also see a link between diagnosis and MMP7, a previously discovered 
biomarker for idiopathic pulmonary fibrosis which is categorized as ILD (Rosas et al. 2008). A 
link between diagnosis and AZGP1, another previously studied marker for COPD (Mazur et al. 
2012), was also recovered. FGG and CYP1A1 were found to be linked to cigarette smoking 
history. CYP1A1 is known to convert polycyclic aromatic hydrocarbons, found in cigarette 
smoke, into carcinogens (Walsh et al. 2013), and FGG codes for fibrinogen, a marker for 
inflammation, which is positively correlated with risk of mortality and COPD severity (Mannino 
et al. 2012). 
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2.3.6 Recovering Functional Relationships 
 
Figure 2.5 Counts of GO terms with uncorrected p < .05 for groups of genes with expression variables linked to 
each discrete clinical variable in: a. MGM networks at different values of λ and b. qp-graphs at different values of q. 
Edge thresholds for qp-graphs were chosen to select similar numbers of connected genes to an MGM network with λ 
= .1 
 
We also compared the functional relevance of MGM networks learned with StEPS and those 
learned by qp-graphs (Tur and Castelo 2012), another method for learning networks over mixed 
data. Like SCGGM, qp-graphs do not attempt to learn edges between two discrete variables, but 
qp-graphs do not make a linearity assumption about the discrete variables. To assess the 
biological relevance of networks learned at different levels of sparsity, we performed enrichment 
analyses on genes with expression variables linked to each clinical variable. For each group of 
genes linked to each clinical variable we counted GO terms with an uncorrected enrichment p < 
.05 (via Fisher’s exact test). These counts are shown in Figure 2.5. Since each clinical variable 
represents a phenotype, we would hope that genes linked to those variables share similar 
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biological function as measured by functional enrichment. We would like to choose a value of λ 
that maximizes the number of enriched GO terms.  
The setting of λ =  .1 recovers the most annotations for diagnosis, FEV1 and FVC, and 
also corresponds to an instability threshold of ! =  .1. qp-graphs output a “non-rejection rate” for 
each edge, which corresponds to the number of different conditional independence tests that 
rejected the presence of each edge. To predict edges, this output needed to be thresholded, so we 
chose thresholds that produced similar numbers of edge predictions to λ =  .1. While qp-graphs 
perform comparably well to MGMs in this test, we found the learning procedure to be very 
computationally expensive. On a quad-core laptop, learning a qp-graph with q = 25 took over 3 
hours (running time scales linearly with q) while learning an MGM took 4.4 minutes on average 
when the iteration limit was reached.   
2.3.7 Evaluating MGM in Classification Tasks 
We also evaluated MGMs for predicting the status of a given target variable. We chose the lung 
disease diagnosis as a clinically relevant target variable. The MGM was compared to SVM and 
lasso. We optimized the settings of SVM, lasso and our mixed models to maximize the 8-fold 
cross-validation accuracy of predicting lung disease diagnosis using the 530 expression variables 
and 7 clinical variables. For SVM, we found that a linear kernel worked best on this data. For 
lasso and MGM, the parameter scan found that λ = 0.05 maximized this accuracy. Figure 2.6a 
shows a comparison between the optimized classification accuracies of these three methods. For 
MGM classification, we expected similar results to lasso because the conditional distribution of a 
discrete variable in the mixed model reduces to a (multivariate) logistic regression. It is 
interesting to see that the generative MGMs are not significantly different from discriminative 
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lasso and SVM models in this experiment. While ! =  .05 maximized the cross-validation 
accuracy for MGMs, Figure 2.6b shows that the StARS selected sparsity values of λ =.1 and .2 
do not perform significantly worse than ! =  .05. Ιn addition, we ran experiments using StEPS 
with settings of [!!!, !!" , !!!] = [.1, .1, .2] and [!!! , !!" , !!!] = [.2, .2, .3] which correspond to 
instability thresholds of ! =  .1 and ! =  .05, respectively, and found that these changes did not 
significantly alter classification performance. 
a b  
Figure 2.6 a. 8-fold cross validation accuracies for COPD/ILD classification using different methods b. 
Regularization effects on classification accuracy (with error bars of 1 standard deviation). 
2.4 DISCUSSION 
Learning graphical models over variables of mixed type is very important for biomedical 
research. The most widely used types of genomic data include continuous (gene expression, 
methylation, and protein data) and discrete (polymorphism and mutation data) variables. 
Similarly, clinical variables can be either continuous or discrete (numerical, categorical, 
boolean). We are interested in learning graphical models from these heterogeneous data to 
identify significant interactions between variables and uncover important biological pathways. 
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As an added advantage, a learned network and joint probability can be used to ask an arbitrary 
number of classification questions over the data without the need for retraining each time 
(Tsamardinos et al. 2003). These models would be broadly applicable to biological network 
inference, biomarker selection and patient stratification. Although calculating the MGM requires 
certain distributional assumptions about the data, the two distributions that make up the model in 
this work, a multivariate Gaussian for the continuous variables and a pairwise Markov random 
field for discrete variables, are well studied and have been successfully applied to many types of 
data. Additionally, using Gaussian copula methods (Liu et al. 2009) in conjunction with MGM 
learning would allow users to relax the normality assumption for the continuous data.  
Our simulation study strongly supports the need for separate sparsity penalty for each 
edge type when learning an MGM. In addition we show the effectiveness of our extension of the 
StARS procedure, StEPS, to select these penalty terms. By using instability estimates from the 
single sparsity parameter model to select parameters for the three parameter model, we are 
making the assumption that each edge type set is independent from the others. We showed that 
StEPS performance under this independence assumption is comparable to a stability selection 
procedure that does not make this assumption. The pay off for StEPS is that we can select three 
parameters in linear time (over the number of parameter values searched) rather than cubic time. 
StEPS is a general methodology, which can be applied to a variety of mixed distribution settings, 
and will be especially useful in problems with many different edge types. 
One could argue that StEPS substitutes an arbitrary setting of ! for an arbitrary setting of 
the instability threshold, !. As Liu et al. point out, ! has a more intuitive meaning than !, and we 
feel that setting this threshold compares to the common practice of setting an arbitrary 
significance threshold for rejecting the null hypothesis. Our results from applying StEPS to 
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MGMs highlights the fact that the same setting of ! applies well to all edge types while different, 
edge type specific settings of ! are required for accurate edge recovery. Although it is possible to 
set the sparsity parameters based on some prior knowledge of the expected number of edges in 
the network, the data driven methods we present here allow for wide application of MGMs to 
domains where such knowledge is not available. 
Furthermore, we show that our approach to MGM learning is competitive with a state-of-
the-art eQTL learning method, SCGGMs. Although SCGGMs can be learned more quickly than 
our MGMs due to the fact that they treat all variables as continuous, we showed that MGMs have 
a clear advantage when the discrete variables have non-linear relationships with the continuous 
variables. The assumption of linearity is common in eQTL learning and it makes sense in the 
haploid yeast datasets (e.g. (Brem et al. 2005)) used in the SCGGM study. In more complex 
organisms, however, an MGM that can handle non-linear interactions may be necessary. 
While we had difficulty setting the discrete-discrete edge penalty in the lung dataset, we 
were still able to show the utility of MGM based analysis on biological data. Also, results from 
our classification experiment were robust to variation in the setting of this parameter. We do not 
expect MGMs to perform better than standard classification methods because they minimize the 
prediction error of the classification problem directly while the pseudolikelihood optimization in 
the MGM must take into account the relationships between all of the variables, not just between 
the target variable and the rest. Our results show, however, that the MGM-based classification is 
comparable to standard methods while offering two key advantages: (1) the same trained MGM 
can be used to make predictions about any variable without additional learning, and (2) the graph 
structure allows us to look at the second neighbors of the target variable and beyond for possible 
functional significance.  
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2.5 CONCLUSIONS 
Mixed graphical models are becoming popular in the statistics and machine learning literature, 
and there is a lot of potential for their application to high dimensional biological data. We have 
broached that potential in this study. We showed that MGMs can accurately learn undirected 
graphical models over a mixture of discrete and continuous variables in a high dimensional 
setting. In addition, we showed that using a separate sparsity parameter for each edge type in a 
graph can significantly improve edge recovery performance. These separate parameters can 
account for the differences in both the difficulty of learning such an edge and differences in the 
sparsity of edge types in the true graph. Finally, we showed that stability based methods are well 
suited for model selection in this setting and that our method StEPS allow us to perform a search 
over the sparsity penalties in linear time. 
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3.0  CAUSAL SEARCH WITH MIXED VARIABLES 
In this chapter we shift from searching for undirected graph structures to directed structures. 
Directed graphical models are closely related to undirected models in that they both encode 
conditional probability relationships between variables, but they differ in their assumptions and 
ability to represent certain structures. The power of directed models come with their ability to 
encode causation, which is especially desirable in the study of biological systems. Of course, 
inferring causation from observational data is a difficult task, but these predictions can guide 
interventional studies to better understand these systems. We will show in this chapter that an 
undirected model learned over data that is generated from a directed graph is a superset of the 
true graph (specifically, a moralization of the true graph). This fact suggests the strategy that we 
adopt in this chapter of first learning an undirected graph using the methods we presented in 
chapter 2, and then filtering and orienting our predicted edges using a directed graph search 
algorithm.  
3.1 CHAPTER SUMMARY 
Graphical causal models are an important tool for biomedical research because they can 
simultaneously represent both the influence pathways and complex, multivariate probability 
distributions that are useful for modeling biological data. Learned models can be used for 
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classification, biomarker selection, and functional analysis. These models are generally designed 
to handle only one type of data, however, and this limits their applicability to a large class of 
biological datasets with both continuous and discrete variables. To address this issue, we develop 
new methods that modify and combine existing methods for finding undirected graphs with 
methods for finding directed graphs. These hybrid methods are not only faster, but also perform 
better than the directed graph estimation methods alone for a variety of parameter settings and 
data set sizes. When applied to breast cancer data, our methods recovered relevant connections 




Commonly studied biological data are multi-modal: they include both discrete variables 
(polymorphisms, mutations) and continuous variables (gene expression, methylation, and protein 
data). The sizes of relevant databases containing these data have become enormous. In many 
problems, the number of potentially relevant variables and cellular pathways demands the aid of 
fast, accurate, computerized search methods for identifying causal relations. These methods 
produce network models, represented as directed graphs or collections of directed graphs, that 
can provide guidance to experimentalists and clinicians and are useful for classification and 
prediction of clinical outcomes. A number of such methods have been developed in the past, but 
they typically assume (for proof of asymptotic correctness) that all variables are of the same 
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distribution type—categorical (multinomial), Gaussian, conditional Gaussian, or linear non-
Gaussian—but not of the mixed types characteristic of biomedical data. In this paper, we test 
existing and develop new methods to learn directed graphs over mixed data types.  
Regarding existing methods, we test PC-stable and CPC-stable (Colombo and Maathuis 
2014). PC-stable is a modification of PC (Spirtes and Glymour 1991), the oldest correct 
algorithm for searching for directed acyclic graphs when there are no feedback relations and no 
unrecorded common causes and sampling is independent and identically distributed. PC-stable 
allows for parallelization and produces graph estimates that are independent of the ordering of 
the input variables. PC-stable relies on conditional independence tests, which can easily be 
varied according to the distributions of the variables. Similarly CPC-stable is the order 
independent variant of Conservative PC (CPC) (Ramsey et al. 2006), which modifies the edge 
orientation procedure of PC to make it robust to ambiguous conditional independence test 
results. 
The main idea behind our two new algorithms is to first learn the undirected graph over 
mixed data types and then prune-and-orient this graph using methods derived from existing 
algorithms for directed graph learning. Undirected graphs are found using a modified version of 
the method of (Lee and Hastie 2013) (which we call MGM for Mixed Graphical Model). For the 
prune-and-orient step we use the strategies implemented in PC-stable (MGM-PCS) and CPC-
stable (MGM-CPCS). The directed search algorithms rely on testing the conditional 
independence of pairs of nodes using larger and larger conditioning sets. The pairwise Markov 
property of undirected graphical models tells us that the absence of an edge in an undirected 
model implies that the two nodes incident to that absent edge are conditionally independent 
given all other variables. So, another way to think of our approach is that by learning an 
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undirected graphical model, we are performing pairwise independence tests conditioned on all 
other nodes in the network. Edge orientation is only implied by absence from the conditioning 
set, so because all nodes are in the conditioning sets for the undirected search step, this procedure 
should not lose information needed by the directed search step to make edge direction 
predictions. In addition to our newly proposed algorithms, this chapter contributes an in-depth 
study of constraint-based causal learning algorithms on high-dimensional mixed data, which is a 
currently underdeveloped area in the causal learning literature. 
3.2.2 Graphical Structures 
Graphical models represent families of probability distributions restricted by conditional 
independence relations between their variables. Undirected graphical models represent 
distributions in which a variable, X, is independent of all other variables in a system given the set 
of variables directly connected to X by an edge (i.e., variables adjacent to X), and any two 
variables connected by an undirected path are associated. Directed graphical models often 
restrict the network structures to directed acyclic graphs (DAGs), and represent distributions in 
which a variable X is independent of all other variables conditional on its Markov Blanket: the 
parents of X (direct causes of X), the children (direct effects) of X, and the parents of the 
children of X. Two variables are dependent or conditionally dependent if they are represented by 
a d-connection relation (Geiger et al. 1990). The essential difference is that for an undirected 
graph a structure ! − ! − ! represents that X and Z are associated but X is independent of Z 
conditional on Y. As a shorthand for this last relationship we write X ⊥ Z | Y. For a DAG with 
the same adjacencies, the independence relations depend on the orientations of the edges: if ! → ! ← ! (this is called a v-structure) then X and Z are independent but they become 
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dependent when conditioned on Y; the independence relations for other orientations of the edges 
in the example are the same as for undirected graphs. When the distribution accords with the 
structure ! → ! ← !, an undirected graph search will return an undirected graph in which X and 
Z are connected by an edge (this is called a moralized graph). These basic properties suggest a 
search strategy that finds an undirected moralized graph, prunes the edges introduced by the v-
structures and directs the remaining edges Here we consider using the Lee and Hastie algorithm 
for undirected graph search and then pruning and orienting edges by PC-stable or CPC-stable. 
We contrast this strategy with using the original PC-stable or CPC-stable procedures directly on 
mixed data types. 
3.2.3 Related Work 
Recently, learning a sparse undirected graph structure over multi-modal datasets has attracted 
attention (Bøttcher 2001; Romero et al. 2006; Tur and Castelo 2011; Cheng et al. 2013; 
Fellinghauer et al. 2013; Lee and Hastie 2013; Chen et al. 2014; Yang et al. 2014). There is 
publically available software for several of these methods (Tur and Castelo 2011; Fellinghauer et 
al. 2013; Lee and Hastie 2013). The Tur and Castelo method is not able to learn connections 
between categorical variables, so their approach is appropriate for the study expression 
quantitative trait loci (eQTLs). But, their model does not allow for analysis of downstream 
discrete clinical variables, for example. A number of proposals suggest a nodewise regression 
approach for learning networks over a variety of distributions of continuous and discrete 
variables (Cheng et al. 2013; Fellinghauer et al. 2013; Chen et al. 2014), Lee and Hastie (Lee and 
Hastie 2013) propose optimizing the pseudolikelihood of a mixed distribution over Gaussian and 
categorical variables. We developed our algorithms using Lee and Hastie’s method as a starting 
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point, both because we will only look at Gaussian and categorical variables in this study and 
because their approach involves learning fewer parameters than with nodewise regression 
methods. 
The idea of using an undirected method to estimate a superstructure of the true graph, and 
then restricting the search space of a directed search algorithm to the superstructure has 
previously been studied for continuous, possibly non-Gaussian data with linear interactions 
between nodes (Loh and Bühlmann 2014). Like our proposed method, Loh and Bühlmann first 
find an undirected graph which serves as an estimate of the moralization of the true graph, and 
then use this undirected graph as an estimate for a directed search method. The two primary 
differences between this study and our proposals are that Loh and Bühlmann only look at 
continuous data in their study, and that the directed search is a score-based method while we 
focus on constraint-based directed search methods here.  
Adapting score-based methods to mixed data is a challenging problem that we are very 
interested in. The concept behind score-based methods is to efficiently search over the space of 
DAGs to find the structure that has the best score given the data. In general, these scores take 
advantage of the fact that joint probability distributions represented by DAGs are factorizable, so 
adding or subtracting edges from the estimated graph only require re-calculating scores of the 
incident nodes. Scores are usually related to likelihood calculations, for example, the Bayesian 
information criterion (BIC) is commonly used for continuous data and is calculated by 
penalizing the log-likelihood for the degrees of freedom and sample size. The challenge is to find 
a mixed score that is factorizable and efficient to compute. Preliminary experiments showed that 
a mixed BIC score based on Lee and Hastie’s pseudolikelihood presented in chapter 2 could 
recover small graphs of ~10 variables, but was too computationally expensive to use on larger 
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graphs. This is an open area of research, but should a useable score for mixed data be developed, 
these methods can take advantage of an initial undirected graph by using it to restrict the search 
space of the score-based search algorithm. 
3.3 MATERIALS AND METHODS 
3.3.1 Simulated Data 
We simulated data from 2 sizes of networks with 50 directed graph structures each. Our low 
dimensional (LD) datasets consisted of 500 samples drawn from a network structure of 50 
variables, 25 Gaussian and 25 3-level categorical. The high dimensional (HD) datasets consisted 
of 100 samples drawn from a network structure of 200 variables, 100 Gaussian and 100 3-level 
categorical. The structures are sampled uniformly from the space of all directed acyclic graphs 
(DAGs) with maximum node degree of 10 and a maximum of average node degree of 2.  
The relationships between variables are set up in a similar fashion to (Lee and Hastie 
2013). Here, for an edge ! → !  we refer to X as the parent and Y as the child. Parents of the 
Gaussian variables contribute linearly to the mean of each child; the value of continuous parents 
is multiplied by an edge parameter and the value of discrete parents is associated with an edge 
parameter where a separate edge parameter is specified for each category of the discrete variable. 
Parents of discrete variables contribute log-linearly to the probabilities of each category, with 
separate parameters for each category of the child variable. With this set up, each edge 
connecting two continuous variables (cc) depends on 1 edge parameter, each edge connecting a 
continuous and a discrete variable (cd) depends on a vector of 3 parameters and edges 
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connecting two discrete variables (dd) depend on a 3 by 3 matrix of 9 edge parameters. In order 
to ensure identifiability, the cd parameter vector, and the rows of the dd parameter matrix are 
constrained to sum to 0 leaving these edges with 2 and 6 degrees of freedom, respectively. Edge 
weights were drawn uniformly from the union of the regions [-1.5, -1] and [1, 1.5]. For cc edges 
the parameter is equal to the weight; for cd edge parameters we draw a vector three values 
uniformly from [0,1] and shift and scale the values so they sum to zero and the largest parameter 
is equal to the edge weight; for dd edge parameters we draw one vector of three values as with cd 
edges  and set the rows of the matrix as the three permutations of this vector. Depending on the 
graph structure, there may be covariance between parents of a node, but since cycles are not 
allowed, this will take the form of a feed forward loop. 
To generate data from these distributions we used TETRAD (version 5.3.0, 
https://github.com/cmu-phil/tetrad), a Java package for causal modeling that uses linear or non-
linear structural equation models (SEMs) to generate data from network distributions. Our fork 
of TETRAD can be found at https://github.com/ajsedgewick/tetrad/. In the continuous case, zero-
mean, Gaussian error terms with standard deviation uniformly drawn from the interval [1, 2], are 
drawn for every variable and then the variable means are resolved. In DAGs this resolution is 
trivial as we can start from root nodes with no parents and propagate downwards. To make this 
process accommodate categorical distributions, we use a uniform draw over [0, 1]  as an error 
term for each discrete variable and this term is used to determine the value of the variable given 
the probabilities of each category. In generating simulated models, these probabilities that are 
then updated in the same way as are the means of the continuous variables. This approach 
ensures convergence of each discrete variable for each sample. 
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3.3.2 Biological Data 
The breast cancer dataset was obtained from The Cancer Genome Atlas (TCGA) (Cancer 
Genome Atlas 2012). This data (BRCA, n=448 samples) included RNA-seq data normalized 
with RSEM for 20530 transcripts, and clinical variables (PAM50 subtypes, Progesterone, 
Estrogen and HER2 receptor status, and tumor and node stage codes). We used only the 500 
genes with the most variant expression across all samples. 
3.3.3 Undirected Graph Search Algorithms 
We use Lee and Hastie’s model (Lee and Hastie 2013) as the basis for both algorithms and we 
refer to the undirected graph produced by this method as an MGM. This model has a form 
similar to a pairwise Markov Random Field (MRF) and learns the undirected graph over mixed 
data by maximizing a penalized pseudo-likelihood over all mixed type variables. Since this 
objective function is convex but not smooth, Lee and Hastie use proximal gradient methods 
implemented in a Matlab library called TFOCS (Becker et al. 2011) for optimization. We 
implemented the MGM model and the accelerated proximal gradient method (Nesterov’s 1983 
method as described by (Becker et al. 2011)) in Java and incorporated it into the TETRAD 
project. 
To improve speed, we made an important change to Lee and Hastie’s optimization 
scheme: instead of waiting for the penalized pseudo-likelihood to converge, we keep track of 
edge changes between iterations of the accelerated proximal gradient method and we terminate 
the search when three iterations in a row have the same graph structure. 
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In our experiments with synthetic data we learned MGM graphs across a range of edge 
sparsity penalties for the Lee and Hastie algorithm, 7 values evenly spaced on the log2 scale over 
the range . 05 ≤  ! ≤  .4. For the HD data we add two values to extend this range to ! ≤  .8. For 
simplicity, in these experiments we use the same ! edges connecting different types of variables. 
3.3.4 Directed Graph Search Algorithms 
We compared two popular causal discovery methods, PC-stable and CPC-stable, implemented in 
TETRAD, with our proposed hybrid methods MGM-PCS and MGM-CPCS. In addition, as a 
proof of concept, we ran experiments with Complementary Pairs Stability Selection (CPSS) a 
stability based method that ensures the predicted network only includes a small proportion of 
low-probability edges that are unlikely to generalize well to small changes in the data. We 
present results from all algorithms using a range of values for the conditional independence test 
threshold: ! ∈ {.001, .01, .05, .1}.  
PC-stable  (Colombo and Maathuis 2014) is a graph search algorithm that is a 
modification of PC (Spirtes and Glymour 1991). PC assumes that the underlying graph is acyclic 
with no latent (unmeasured) variables. The PC algorithm and its descendants depend on 
conditional independence decisions that are made by a user-specified test and significance level, ! (described below). PC starts with a complete graph and in step 1 it sequentially tests all edges 
for independence given conditioning sets of increasing size. Starting with the empty set, these 
conditioning sets are subsequently made up of every set (of the given size) of common neighbors 
of the two nodes incident to the edge being tested. Edges that are found to be conditionally 
independent are immediately removed and not considered in future tests. When an edge is 
removed, the conditioning set that lead to the independence decision is saved. Step 2 directs 
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edges based on the fact that common neighbors of nodes incident to a removed edge that are not 
in the conditioning set must be in a v-structure. It is possible that two implied v-structures will 
induce conflicting edge directions. In the TETRAD implementation of PC-stable this direction 
conflict results in a bi-directed edge: ! ⟷ !. Step 3 further directs edges based on a set of rules 
that ensure the directions will not induce any cycles or new v-structures (Spirtes et al. 2000). PC-
stable modifies PC by waiting to update the edge removals in phase 1 until all tests for a given 
conditioning set size are completed. This leads to an output that is independent of variable 
ordering and allows for parallelization of the independence tests.  
CPC-stable (Colombo and Maathuis 2014) is the variable order independent variant of 
Conservative PC (Ramsey et al. 2006) which revises step 2 of PC, described above to perform 
conditional independence tests with all possible conditioning sets between two nodes, A and C, 
that have had an edge between them removed. The conditioning sets are determined by taking 
subsets of neighbors of the two nodes found in the skeleton graph returned by step 1 of PC, 
described above. For any node, B that is incident to both A and C, the v-structure ! → ! ← ! is 
only predicted if B is not in any separating set S such that A ⊥ C | S. Otherwise no direction is 
predicted from this triplet of nodes. If B participates in some sets that result in the conditional 
independence of A and C and some that result in a conditional dependence, the ambiguity is 
recorded. Since the change to the PC algorithm takes place after adjacency has been determined, 
PC and CPC algorithms will produce the same adjacency predictions. 
MGM-PCS and MGM-CPCS first learns an MGM and then uses the predicted 
undirected graph instead of a full graph as the starting point for PC-stable and CPC-stable 
respectively. 
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CPSS (Shah and Samworth 2013) is an a variation of the Stability Selection 
(Meinshausen and Bühlmann 2010) that both loosens the assumptions on the selection procedure 
(i.e. our network prediction algorithms are “selecting” edges), and tightens the bounds on the 
error rate, allowing for a less stringent threshold. Besides the obvious benefit of tighter bounds, 
the loose assumptions are especially attractive to us, as we would like to be able to substitute a 
variety of algorithms without worrying about violating the theoretical framework of the method. 
As with StARS and StEPS in chapter two, this method works by learning networks over 
subsamples of the data and counting how many times an edge appears. Rather than calculating 
network instabilities from these empirical edge probabilities, edges are selected by simply 
thresholding the probabilities. The threshold is calculated from the number of subsamples, the 
average number of selected edges, and the number of variables using Shah and Samworth’s 
procedure. The user specifies an error control rate where errors are defined as edges that have a 
lower than random probability of being selected in a given subsample. We use a heuristic to 
adapt this method to directed edge recovery: the empirical selection probability of each edge 
direction setting (two directions or undirected) is calculated and thresholded separately. We ran 
CPSS in conjunction with MGM-PCS and MGM-CPCS with ! =  .05 and ! =  .1 for the LD 
dataset, and with ! =  .2 for the HD dataset with error rates ! ∈ {.001, .01, .05, .1}. 
3.3.5 Conditional Independence Tests 
The following test, used by PC-stable and MGM-PCS, is a hypothesis test for conditional 
dependence of two variables, X and Y, given a conditioning set of variables, S. The null 
hypothesis is that X and Y are independent given S, or  ! ⊥ ! | !. By definition, if this null 
hypothesis is true: 
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! !,! !) = ! ! ! !(!|!) 
Rearranging, we find: 
! ! ! =  !(!,!|!)!(!|!) = ! ! !, !) 
So, to test ! ⊥ ! | ! it suffices to test if ! ! ! = ! ! !, !) which is done via likelihood ratio 
test (LRT) of two regressions: 
2 ln  ! θ!"#! θ!" ~ !!(!!!!) 
Where the !s represent the regression coefficients to model X given S with and without Y as an 
additional independent variable. The degrees of freedom, !! and !!, of each variable are 1 if the 
variable is continuous and the number of categories minus 1 if the variable is categorical. 
Although this description uses regressions with X as the dependent variable, the same reasoning 
allows us to use Y as the dependent variable instead. 
The regressions in this test allow us to formulate this test so that any of the variables can 
be continuous or categorical. We preform linear or multinomial logistic regressions if the 
dependent variable is continuous or categorical, respectively. Because of this, if X and Y are of 
different variable types, we have a choice of whether X or Y should be the independent variable 
that determines whether we perform logistic or linear regressions. Our own experiments and 
observations in previous studies (Chen et al. 2014) suggest that a linear regression will give a 
more accurate test result than a logistic regression for these continuous-discrete edges. To handle 
any independent categorical variables in the regression, use the standard practice of converting 
each k-level categorical variable to k-1 binary variables. 
 It is also possible to conduct these tests by regressing Y and S onto X, and using a t-test 
to determine if the regression coefficient of Y is significantly different from 0. If Y is categorical 
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this procedure requires performing a test on each dummy variable associated with Y and then 
combining them using Fisher’s method. The main advantage of using t-tests over the LRT that it 
only requires one regression instead of two, so it is significantly faster. The downside is that in 
our experiments we found that it had less power to detect true edges, and was less robust to low 
sample sizes, particularly on edges that required a logistic regression. Because of this we will 
work exclusively with the LRT based test here. 
3.3.6 Edge Recovery Evaluation 
To evaluate network estimation performance, we compare the Markov equivalence classes of the 
estimated and true networks. Markov equivalence classes represent the variable independence 
and conditional relationships for an acyclic directed graph by removing the direction from edges 
that are free to point in either direction without altering the independence relationships in the 
network. For example, directed graphs ! → ! → !, and ! ← ! ← ! both have the Markov 
equivalence class ! − ! − ! while the graph ! → ! ← ! (v-structure) would remain the same 
when converted to a Markov equivalence class. Thus, Markov equivalent graphs share the same 
variables, have the same adjacencies, and imply the same independence and conditional 
independence relations among their variables. We also consider performance on skeleton 
estimation, (i.e. the set of node adjacencies, without edge orientations). 
We use standard classification statistics to evaluate the recovery of the undirected 
adjacencies from the skeleton of the true graph. Precision, also known as true discovery rate or 
positive predictive value, is the proportion of predicted edges that are found in the true graph. 
Recall, also known as sensitivity or true positive rate, is the proportion of edges in the true graph 
that were found in the predicted graph. For direction recovery we use these same statistics 
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applied to the recovery of only the directed edges in the Markov equivalence class of the true 
graph. So, in the context of direction recovery, precision is the number of directed edges in the 
predicted graph that are found in the true graph out of the total number of directed edges in the 
predicted graph. Bi-directed edges are treated as undirected edges for these statistics because 
they do not give an indication of which edge direction is more likely. These statistics can be 
easily calculated from confusion matrices, which are shown for the undirected and directed graph 
estimation in Figure 3.1. 
a.   
b.  
Figure 3.1 Confusion matrices for edge recovery on a. undirected graphs and b. directed graphs. 
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We use the Matthews correlation coefficient (MCC) (Matthews 1975) as a measure for 
overall recovery performance that strikes a balance between precision and recall. The MCC is a 
formulation of Pearson’s product-moment correlation for two binary variables (i.e. true edge 
indicators and predicted edge indicators). In addition, we use the structural Hamming distance 
(SHD) (Tsamardinos et al. 2006) as a combined measure of adjacency and direction recovery. 
The SHD is the minimum number of edge insertions, deletions, and direction changes, where 
only undirected edges are inserted or deleted, to get from the true Markov equivalence class to 
the estimated equivalence class. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Simulation Experiments 
In order to determine which algorithms have the most general applicability, we performed 
experiments using two different dataset sizes and randomly drawn DAG structures. In addition 
since optimal parameter setting is a difficult problem that may depend on the needs and goals of 
the user, we studied a range of possible parameter settings to show the relationship between these 
settings and edge recovery performance. 
3.4.1.1 Adjacency Recovery  
Figure 3.2 shows the (undirected) adjacency recovery performance of PC-stable, MGM-PCS 
and CPSS on the HD dataset. CPC-stable and MGM-CPCS are not shown because they have the 
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same adjacency predictions as the PC algorithms. Settings of ! < .2 for the MGM-PCS algorithm 
are omitted from the figure because they mostly overlap with the PC-stable curves. Despite the 
apparent overlap, these denser MGM structures do cause a slight decrease in the precision of 
MGM-PCS compared to PC-stable, although this difference is not significant at any of the tested 
settings. For example, at ! =  .05 and ! =  .14, MGM-PCS has an average precision of .739 
(standard error of .0057) compared to PC-stable which achieves mean precision of .744 (standard 
error is .0055). In the limit of ! → 0, the MGM graph will become fully connected so MGM-
PCS becomes equivalent to PC-stable.  
On the other extreme, the highest settings of lambda result in very sparse initial graphs 
which have good precision but poor recall. In general, we see that adding the MGM step 
increases precision of the PC-stable procedure, at a small cost to recall, depending on the sparsity 
parameter setting. We see a similar trend in the LD dataset as well (see Appendix A for 
equivalent figures for the LD data). In addition, all of our algorithms have both lower precision 
and recall on edges involving discrete variables which suggests that they are more difficult to 
learn. This observations differs from the LD setting where we actually achieve the best recall on 
these dd edges, although still diminished precision compared to cc and cd. Finally, these results 
show that CPSS is a good option for users that want to ensure very high precision in their 




Figure 3.2 Precision-Recall curves of edge adjacency recovery on high-dimensional dataset for . 2 ≤ ! ≤  .8 
(represented by different shaped points) and . 001 ≤ ! ≤  .1. For a given setting of  !, the different settings of ! are 




3.4.1.2 Direction Recovery  
Next, we evaluated how well each algorithm was able to recover the directions in the directed 
edges of the true Markov equivalence class. For these tests, the positive class is all estimated 
directed edges, and the negative class is both undirected edges and the absence of an edge. So, an 
estimated edge is only considered a true positive if it correctly identifies both the existence and 
the orientation of the edge. Figure 3.3a shows these results across all of our algorithms. Starting 
from an MGM graph increases direction recovery performance in PC-stable. The main reason for 
this improvement appears to be the fact that PC-stable alone returns a large number of bidirected 
edges and only finds a small number of edges with a single direction. Bidirected edges are 
returned when the v-structure orientation rule in step 2 of PC-stable implies both directions for 
an edge. We treat these as undirected edges in our statistics. Starting from an MGM graph 
reduces the number of bidirected edges and increases the number of directed edge predictions. 
This is evident by the large increase in directed edge recall, but comes at the price of reduced 
precision for higher independence test thresholds, ! ∈ {.05, .1}. 
Figure 3.3b gives us a detailed view of the direction recovery performance of CPC-
stable, MGM-CPCS, and CPSS. As with adjacency recovery we see that as we increase lambda 
we achieve higher precision at the cost of recall. The reduced recall in ! ∈ {.28, .4} is only slight 
combined with a significant increase in precision. We can also see that our heuristic for adapting 
CPSS to directed network recovery is perhaps too conservative as the recall is greatly reduced 
while precision is near perfect. Indeed with this set up CPSS predicts the directions of less than 
10 edges on average, for the most lenient error rate, ! =  .05, so it does not seem to be a useful 





Figure 3.3 Precision-Recall curves of edge direction recovery on high-dimensional dataset for . 2 ≤ ! ≤  .8 and . 001 ≤ ! ≤  .1. a Full range of algorithms and edge types. b Detail view of CPC-Stable and MGM-CPC-Stable  
performance averaged over all edge types. 
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Overall, direction recovery is difficult in high dimensions. While MGM-PCS approaches 
direction recall of .3, this is paired with abysmal precision of less than .5. CPC-stable and MGM-
CPCS give us high precision, but are able to recall less than 15% of true directed edges. Given 
that our heuristic to adapt CPSS to the problem of direction estimation that produces extremely 
high precision but very low recall, there is room for improvement in developing a less stringent 
heuristic. 
3.4.1.3 Combined measures of network recovery 
The Structural Hamming Distance (SHD) is a combined measure of adjacency and direction, that 
gives us an alternative network estimation metric that does not necessitate balancing precision 
versus recall. Table 3.1 shows the “best case” performance of our algorithms, where the 
parameters settings are chosen to maximize the SHD both averaged over all edges, and broken 
down by each edge type. Since SHD is a distance measure, smaller values indicate better 
performance. By this measure, MGM-PCS and MGM-CPCS both significantly outperform their 
counterparts on the HD data. We see a similar trend in the LD data (Appendix A), where MGM-
PCS performs significantly better than PC-stable, while MGM-CPCS has a slight but non-










Table 3.1 Parameter settings with the best SHD performance by edge type 
in high-dimensional data set 
Algorithm !  ! Type SHD 
PC-Stable 
0.01 none all 600.95 (2.25) 
0.01 none cc 130.00 (2.340) 
0.01 none cd 308.40 (4.20) 
0.001 none dd 160.45 (3.24) 
MGM-PCS 
0.01 0.14 all 567.75 (3.34) 
0.05 0.14 cc 108.45 (2.21) 
0.01 0.14 cd 294.70 (3.74) 
0.001 0.1 dd 157.30 (3.28) 
CPC-Stable 
0.01 none all 588.10 (2.37) 
0.05 none cc 111.60 (2.44) 
0.01 none cd 307.05 (4.18) 
0.01 none dd 160.80 (2.85) 
MGM-CPCS 
0.1 0.4 all 564.90 (4.46) 
0.1 0.57 cc 107.05 (2.32) 
0.1 0.4 cd 296.70 (4.17) 
0.1 0.4 dd 157.05 (3.25) 
 
Since the best case performance will be difficult to achieve when the true graph is 
unknown, especially in this setting where a robust parameter setting scheme is not readily 
available, we also show SHD performance versus the number of predicted graph edges. These 
results, presented in figure Figure 3.4 show that for parameter settings for MGM-CPCS that 
produce similar numbers of edge predictions to CPC-stable, the hybrid algorithm can improve 
SHD performance. Very sparse settings of ! result in networks with a large SHD because so 
many edges are missing compared to the true graph. These too-sparse settings of the MGM are 




Figure 3.4 Structural Hamming Distance on high-dimensional dataset for CPC-stable and MGM-CPCS with for . 2 ≤ ! ≤  .8 and . 001 ≤ ! ≤  .1. The lower the SHD, the closer the predicted graph is to the true graph. 
3.4.1.4 Run Time 
We compared the running times of our algorithms at different parameter settings. Figure 3.5 
shows these results for the HD dataset. MGM-PCS and MGM-CPCS are significantly faster than 
PC-stable for sparser settings of !, but significantly slower for low values of ! and low values of !. In the LD data (Appendix A), we see the increase in speed from the MGM step at almost all 
settings of ! and !. It is important to note that our MGM learning method is not parallelized, but 
the directed learning steps are, so a parallelized MGM learning algorithm could result in even 
larger speed improvements. The edge convergence approach we use to learning the MGM is 




Figure 3.5 Average running times with 95% confidence interval error bars of search algorithms on high dimensional 
data. Each row of bars corresponds to a different setting of ! and each color corresponds to a different setting of !. 
Directed search steps were run in parallel on a 4 core laptop. 
3.4.2 Application to Breast Cancer Data 
We applied MGM-PCS to gene expression and clinical data from breast cancer patients curated 
by TCGA (Cancer Genome Atlas 2012). For the analysis we used the 500 genes with the highest 
variance across samples. We also included the clinical variables for hormone receptor status, 
node and tumor staging codes, and PAM50 subtype. PAM50 is a subtyping scheme that uses 
gene expression patterns from 50 genes to categorize tumors (Parker et al. 2009), thirteen of 
which were in the high variance set. We ran MGM-PCS with a sparsity of λ = .2 (selected based 
on stability of edges across subsamples, (Liu et al. 2010)), and α = .05. The output network 
57 
(Figure 3.6) had 8 high variance genes connected to the PAM50 variable, 3 of which were 
among the 13 included in the analysis (Fisher’s test, p=1.83*10-5).  
 In addition, we find a number of predicted edges that are supported by biological 
knowledge. Each clinical variable corresponding to receptor status (ER, PR, HER2) was linked 
with the gene expression profile of that receptor: progesterone receptor with PGR1, HER2 with 
ERBB2, and estrogen receptor with ESR1. We find GATA3 is linked to ESR1, which relates to a 
recent study (Cimino-Mathews et al. 2013) that found GATA3 to be central in luminal (i.e. 
estrogen receptor positive). The lymph node stage variable, which indicates degree of lymph 
node metastasis, in our predicted network was only linked to the expression of E-cadherin gene 
(CDH1). Hypermethylation and decreased expression of CDH1 has been linked to infiltrating 
breast cancer (Caldeira et al. 2006). 
 
Figure 3.6 Predicted subnetwork for breast cancer dataset, with discrete clinical variables shown in red 
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3.5 CONCLUSIONS AND FUTURE WORK 
We have shown that the combination of undirected graph search by optimizing conditional-
Gaussian pseudo-likelihood over mixed data types, followed by directed graph search can 
recover causal information in complex systems containing both Gaussian and categorical 
variables. We have also shown that these methods can recover valuable information in real 
biomedical data. In many cases, our hybrid searches are faster and perform better than the 
directed search steps by themselves. In the worse case, our hybrid algorithms do no worse than 
the single algorithms searches and are slightly slower. 
 In addition to our newly proposed algorithms, this work provides an in-depth study of the 
challenges of causal learning on mixed data types. At both high and low dimensional settings, we 
are able to recover true edges from simulated data with high precision. Recall is more 
challenging, especially of edge direction and at high-dimensional settings. As expected, 
recovering edges and directions involving categorical variables was more difficult in high-
dimensional settings, but this trend was surprisingly not obvious in the low-dimensional setting. 
 Directed MGMs are promising tools for exploratory biomedical research. As shown in 
this chapter and the next, they are able to recover both known and novel relationships between 
variables. We expect further work with these models to yield many more viable hybrid 
algorithms, as an undirected MGM can be adapted to serve as a starting point for a wide range of 
casual discovery algorithms. 
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4.0  APPLICATION TO METASTATIC MELAOMA 
Here we present a case study for integrative data analysis that begins with an application of 
MGM-PCS, described in the previous chapter, to multimodal data from a cohort of metastatic 
melanoma patients, and follows our work to both validate and study the mechanism behind a 
biomarker identified by our algorithm. This study serves as an example of a successful 
application for our network learning algorithm for identifying a direct causal relationship 
between a single nucleotide polymorphism in the PARP1 gene, rs1805407, and response to 
chemotherapy. Through a combination of computational work performed by us and cell line 
experiments performed by Irina Abecassis and Maria Kapetanaki, we found evidence for a 
mechanism that begins the explain the causal link between these two variables. Because this 
mechanism does not involve any of the other variables that were measured in the melanoma 
cohort, it confirms our initial prediction of a direct connection between the variables given the 
available data. 
4.1 CHAPTER SUMMARY 
Personalized cancer therapy relies on the identification of patient subsets with differential 
responses to therapeutic interventions and stratifying them to maximize the therapeutic index or 
administer alternative regimens. We applied MGM-PCS to analyze mRNA and microRNA 
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expression, DNA methylation, SNP, and clinical variables in a cohort of metastatic melanoma 
patients in order to identify direct causal interactions between variables. Our results show that 
ten gene expression, four methylation variables and SNP rs1805407 are directly linked to 
response to chemotherapy. SNP rs1805407 is located in PARP1, a DNA repair gene critical for 
chemotherapy response and for which FDA-approved inhibitors are clinically available 
(olaparib). We demonstrate that PARP inhibitors are synergistic to chemotherapy in cancer cells 
carrying the PARP1 variant, but they are additive or antagonistic to chemotherapy in wild-type 
cancer cells. Additionally, we found that TCGA melanoma and ovarian cancer patients that carry 
this SNP have increased expression of the PARP1-003 splice variant, a truncated form of 
PARP1. Based on these results we postulate that SNP rs1805407 is directly linked to increased 
sensitivity to PARP inhibitors, potentially through enhanced PARP1 trapping, in cancer cell lines 
from various histologies and most importantly ovarian cancer. Our results suggest that the 
combination of chemotherapy and PARP1 inhibition may benefit the carriers of the PARP1 SNP 
rs1805407. These findings demonstrate the utility of MGM-PCS and will inform personalized 
therapy to select patients more likely to respond to PARP inhibitors.  
4.2 BACKGROUND 
Cancer is among the leading causes of morbidity and mortality worldwide, with approximately 
14 million new cases and 8.2 million cancer related deaths in 2012 (World Cancer Report 2014 
and (de Martel et al. 2012)). The number of new cases is expected to rise by about 70% over the 
next 2 decades. Advances in cancer management have improved the overall outlook of patients 
with metastatic malignancies but chemotherapy remains a mainstay of treatment for most 
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common cancers. Virtually all patients develop resistance to chemotherapy after prolonged 
exposure given the first order kinetics of cytotoxics that generally cannot eradicate cancer. 
Understanding the mechanisms of this resistance presents new opportunities to improve the 
therapeutic index of cytotoxic agents and identify novel drug targets. 
A large proportion of cytotoxic agents exert their effect through DNA damage. Thus, 
DNA repair pathways constitute cells’ main resistance mechanisms and potential drug targets. 
Base excision repair, a predominant pathway for single strand break (SSB) damage repair, 
utilizes a family of related enzymes termed poly-(ADP-ribose) polymerases (PARP), which are 
activated by DNA damage (Luo and Kraus 2012). Given the critical role of PARP1 in base 
excision repair, PARP inhibition emerged as a therapeutic target and early studies demonstrated 
dramatic potentiation of chemotherapeutic agents in the presence of PARP inhibition (Bryant et 
al. 2005; Farmer et al. 2005). Recent evidence indicates that, in addition to the catalytic 
inhibition of PARP activity, PARP inhibitors (PARPi) induce cytotoxic PARP-DNA complexes 
through PARP “trapping” that augment the cytotoxicity of alkylating agents. It is therefore of 
utmost importance to identify molecular features that act not only as biomarkers for patient 
stratification but also offer insights into the mechanisms of resistance to chemotherapy. 
Metastatic melanoma remains an excellent model for chemotherapy resistance given its 
refractory nature, despite the fact that current management of metastatic melanoma is mostly 
based on non-chemotherapy based strategies (e.g., targeted and immune-based therapies). 
In this study, we apply a novel graphical method we developed, MGM-PCS, to high-
throughput data from a cohort of metastatic melanoma patients on chemotherapy. We identified 
various features that were directly linked to response to treatment, including a SNP in the PARP1 
gene that is highly predictive of resistance to chemotherapy. We went on to characterize the 
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impact of this PARP1 variant on PARPi sensitivity and demonstrated its utility as a predictive 
biomarker of PARPi sensitivity in vitro. Given the role of PARP1 in DNA repair, we propose 
this SNP as a biomarker for PARPi sensitivity to guide patient selection for treatment regimens 
incorporating PARPi’s in combination with alkylating agents. 
4.3 MATERIALS AND METHODS 
4.3.1 Melanoma study design 
Using a retrospective cohort study design, we evaluated 69 patients with metastatic melanoma 
who were treated with alkylator-based chemotherapy at the Melanoma Center of the University 
of Pittsburgh Cancer Institute (UPCI). Frozen tissues were available from metastatic lesions on 
21 patients and formalin-fixed paraffin embedded tissues from 45 patients (total n=69). Only pre-
treatment tumor specimens were included in this analysis. In addition, chemotherapy regimens 
studied were primarily single-agent dacarbazine (DTIC), single-agent temozolomide (TMZ) or 
DTIC-based combinations (including CVD, Cisplatin + Vinblastine + DTIC). Response to 
chemotherapy was defined as documented objective tumor regression upon treatment. Patients 
with disease progression after 2 cycles of chemotherapy or with stable disease lasting less than 4 
months were considered non-responders. 
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4.3.2 Using Mixed Graphical Model learning (MGM-PCS) to integrate -omics and clinical 
data 
We normalized the data for use with MGM-PCS in the following way. Each continuous variable 
was transformed so that its distribution across patients was normal with truncated tails using the 
non-paranormal method (Liu et al. 2009). In addition, the 10% of SNPs with the lowest variance 
were filtered out. 
To filter this large dataset down to a size that was feasible to use with MGM-PCS, we 
filtered the variables based on their pair-wise correlation with the response to treatment variable. 
In order to accurately calculate correlation between this discrete variable and other discrete or 
continuous variables, we used a generalized correlation metric, described below. With this 
metric, we filtered the data down to the 1000 variables that were most correlated with response 
to treatment.  
4.3.3 Filtering with generalized correlation 
We use the following strategy to measure association between a continuous and categorical 
variable or two categorical variables. We would like to calculate the equivalent of Pearson’s 
product moment coefficient for each possible pairing of these variables. The general formula for 
Pearson’s correlation between two vectors of observations, X and Y, with means !! and !! and 
standard deviations !! and !! is !!" = !"#(!,!)!!!!  where covariance is defined as !"# !,! = ![ ! −  !! ! − !! ]. This is a standard calculation for pairs of continuous variables because 
mean and standard deviation are well defined. For pairs of binary variables, these values are also 
well defined, and this formulation is called the Matthews’ Correlation Coefficient. For 
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categorical variables we can calculate the covariance on a category by category basis. So for a 
categorical X continuous Y, we can focus on a, one of the categories of X when calculating a 
sample covariance: !"# !! ,! =  ! !! −  !!! ! − !! =  !!!! [ ! !! = ! −  !! !! −!!!! !! ] where !(!! = !) is an indicator function that is 1 when !! = ! and zero otherwise, and !! =  !! !(!! = !)!!!!  or the empirical probability of observing a in X. Since ! !! = !  is 
equivalent to a Bernoulli random variable now it is easy to see that the sample standard deviation 
is !!! =  !!!! !! 1− !! . Similarly, if both X and Y are categorical we now look at each 
possible pairing of categories separately so !"# !! ,!! =  !!!! [ !(!! = !)−  !! (!(!! =!!!!!)−  !!)] where !! is the empirical probability of observing b in Y. So, in a discrete-continuous 
pair, we now have a vector for the covariance and a vector for the standard deviations 
corresponding to the different levels of the categorical variable, we use the !! norm to calculate a 
single score from these vectors (where X is categorical): !!" = !"# !,! !!! !! . In the discrete-
discrete case we have two matrices corresponding to the possible pairs of levels in the two 
variables, and we combine them with the Frobenius norm: !!" = !"# !,! ! !!!! ! . Both of these cases 
result in non-negative values so to make the continuous-continuous values comparable with the 
others we take the absolute value so scores for all pairs of edges fall on the interval [0,1]. 
One motivation for this approach is that these sample covariances turn out to be 
proportional to the partial gradients of negative log pseudolikelihood in a factorized (i.e. zero 
edges) MGM as described above with respect to the edge parameters and variable levels (see 
(Lee and Hastie 2013) supplement). Namely: !!!!!" = −2 ∗ (! − 1) ∗ !"#(!,!),  !!!!!"(!) = −2 ∗
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(! − 1) ∗ !"# !! ,!   and !!!!!"(!,!) = −2 ∗ (! − 1) ∗  !"# !! ,!!  where X is the indexed by i 
and Y is indexed by j in the MGM and the pairs of X and Y are continuous-continuous, discrete-
continuous, and discrete-discrete respectively. 
4.3.4 Patient data from The Cancer Genome Atlas 
We collected publically available RNAseq and genotype data generated by the The Cancer 
Genome Atlas (TCGA) Research Network (http://cancergenome.nih.gov/) for 418 ovarian cancer 
tumors and 293 melanoma tumors. RSEM (Li and Dewey 2011) quantified transcript abundances 
from TCGA were used for genome-wide mRNA expression profiling. We used Kallisto (Bray et 
al. 2015) to quantify PARP1 splice variant abundance. Genotype data came from the Affymetrix 
Genome-Wide Human SNP Array 6.0 platform. 
4.3.5 SNP imputation on TCGA samples and NCI-60 cell lines 
We obtained NCI-60 data from Cell Miner in June 2013 (http://discover.nci.nih.gov/cellminer/). 
For those cell lines or TCGA samples for which the identity of SNP rs1805407 was not available 
we used imputation to infer its identity. Using SNAP (Johnson et al. 2008) we found 51 SNPs to 
be in perfect linkage disequilibrium (LD) with rs1805407 (R2 = 1). Of these, 9 variants were 
covered by the Affymetrix SNP Array 6.0 used by the TCGA. To determine the rs1805407 
genotype in TCGA samples we used birdseed calls (Korn et al. 2008) available from the 
genotype data. Only samples with a birdseed confidence less than 0.1 or where all 9 SNPs in 
perfect LD agreed with the birdseed call were used. 
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4.4 RESULTS  
4.4.1 Identifying predictive markers of treatment for metastatic melanoma patients 
Our melanoma dataset consisted of gene expression, microRNA expression, DNA methylation, 
and data from the selected SNP panel. We used MGM-PCS to learn a network over the top 1000 
features most correlated (pairwise) with “response” clinical variable, a binary variable indicating 
response/no response to TMZ treatment dichotomized at presence of a response or stability of 
disease at 4 months of therapy. The 1000 most correlated features in the input dataset included 
557 mRNA expression probes, 425 methylation probes, 14 miRNA probes and 4 SNPs. BRAF 
mutation status was also included in the input variables to see if it had an effect on any of the 
features linked to response, although its direct correlation with it in this dataset was poor 
(R2=0.025). The largest interconnected output network included 20 features directly connected to 
the response variable in our initial (undirected) learned network (Figure 4.1a). We emphasize 
that these features were connected to the response variable not only because they have high 
pairwise correlation with it (Figure 4.1b), but also because they are dependent on response even 
when conditioned on all other variables in the filtered dataset. In this sense, they represent direct 
(causal) interactions and not simple biomarkers. From the 20 features initially connected to 
response in the undirected MGM model, 15 were left connected after the causal filtering (Figure 
4.1a, black lines). A methylation feature for DXS9879E (LAGE3) is one of them, and it has been 
linked to survival in non-small cell lung cancer (Lokk et al. 2012). Notably, this important 
feature is not present in the top 20 (pairwise) correlated features with response, as other 
(indirect) interactions yielded higher pairwise correlation values. ID2 expression is also directly 
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linked to response, and is known to induce growth and proliferation in squamous cell carcinoma 
(Wang et al. 2012a). 
a.  
b.  
Figure 4.1 a. Conditional Gaussian sub-network around response to treatment with edge filter. Blue nodes represent 
methylation probes, green nodes represent mRNA expression probes and yellow nodes represent SNPs. Dashed red 
lines indicated edges removed by filtering step. b. Heatmap of directly connected links to response to TMZ. Black 
bars show rs1805407 status and response to treatment. Rows marked with green are mRNA expression profiles and 
those marked with blue are methylation profiles. 
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4.4.2 SNP rs1805407 in PARP1 is strongly associated with worse outcome in melanoma 
patients 
SNP rs1805407 (PARP1) is the only SNP in our dataset that is directly linked to response. We 
found this SNP to be an excellent predictor of worse outcome since all 21 patients that had the 
SNP (C/T or C/C) showed no response to TMZ treatment while of the remaining 48 patients with 
rs1805407 T/T, 22 responded to treatment (p-value=4.6e-5). Because of the strong direct (causal) 
association, the role that PARP1 plays in repairing TMZ mediated DNA damage, and the 
availability of PARP inhibitors, we decided to investigate this finding further. rs1805407 is 
located on the 2nd intron of PARP1, ~4 Kbp downstream of the PARP1 transcription start site 
and 35 bp downstream of the 3’ splice site of exon 2. We used SNAP (Johnson et al. 2008) to 
find other SNPs in strong linkage disequilibrium (LD) with rs1805407. The CEU population 
panel of 1000 Genomes pilot 1 contained 51 variants in perfect LD (R2 = 1) (Appendix B, Table 
B.1) with our selected variant. Of these, two are upstream of the transcription start site (TSS). 
Specifically, rs6665208 is 3,573 bases upstream of the PARP1 TSS and overlaps with ENCODE 
ChIP peaks for MAFF and MAFK, which are both related to blood cancers (Balkhi et al. 2006). 
rs2077197 is 238 bases upstream and overlaps peaks for AP-2α, CTCF, HA-E2F1, ZBTB7A, 
Pol2, CEBPB and YY1. Many of these factors are related to cancer. For example, AP-2α and 
ZBTB7A are known tumor suppressors (Liu et al. 2014; Su et al. 2014). CEBPB plays a role in 
senescence of prostate cancer cells (Barakat et al. 2015) and in multi-drug resistance (Riganti et 
al. 2015). E2F1 is induced by DNA damage (Lin et al. 2001). CTCF is an insulator protein and 
YY1 participates in long-range chromosomal interactions. 
Another SNP (rs1805405) is also in perfect LD with rs1805407 (R2 = 1) and is annotated 
as a ‘Splice region variant’ because it is located 5 bp upstream from the splice site between 
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intron 2 and exon 3. Finally, we found a strong dependence between rs1805407 and two other 
SNPs that have been previously associated with melanoma susceptibility: rs3219090 (D’ = 1, R2 
= 0.43 (Macgregor et al. 2011) and rs2249844 (D’ = 1, R2 = 0.46) (Davies et al. 2014).  Due to 
high LD values with rs1805407 none of them was included in our original SNP panel. 
4.4.3 SNP rs1805407 is related to decreased cytotoxicity of alkylating agents in cell lines 
with the variant 
Given that rs1805407 is associated with worse outcome of melanoma patients treated with TMZ 
and that PARP1 has a critical role in repair of DNA lesions caused by TMZ, one plausible 
hypothesis is that rs1805407 is either associated with increased PARP1 expression and/or 
activity or decreased PARP1 trapping after treatment with alkylating agents (Murai et al. 2012; 
Murai et al. 2014a; Murai et al. 2014b). We looked for more insights into the role of rs1805407 
in cell response to various drugs. The NCI-60 Cell Miner database (Reinhold et al. 2012) 
contains the response of 60 cell lines to ~50,000 compounds. We evaluated whether drugs affect 
differentially the cell lines that have at least one copy of rs1805407 (C/T or C/C) vs WT (T/T). 
The Affymetrix 500k SNP arrays used by Cell Miner did not include rs1805407, so we used the 
k-nearest neighbors method with three of the 51 perfectly correlated variants with probes in the 
array (rs1073991, rs10799349 and rs3219027) to infer the rs1805407 genotype in each cell line. 
Analysis of the IC50 values in cell lines predicted to have at least one allele of rs1805407 (n = 23; 
C/T or C/C) vs wild type (n=37; T/T) showed statistically significant resistance or sensitivity to 
four compounds, three of which are alkylating agents with action similar to TMZ (TMZ is not 
included in the NCI-60 dataset) (Table 4.1). Cell lines containing the PARP1 SNP showed only 
a slight increase in sensitivity to the PARPi olaparib used as a single agent (Table 4.1). 
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Carmustine and Cyclophosphamide are classical DNA damaging alkylating agents. Parthenolide, 
a compound that induces apoptosis in acute myelogenous leukemia (AML) and progenitor cells 
(Guzman et al. 2005). Increased sensitivity was observed for Irofluven, an alkylating agent that 
inhibits DNA replication (Wang et al. 2007).  For comparison purposes, we also added the 
PARP1 inhibitor Olaparib (which is not statistically significant when used as single agent). 
These results are compatible with the hypothesis that SNP rs1805407 (or one of the 51 SNPs in 
perfect LD with it) may cause increased PARP1 expression and/or activity thus helping to repair 
the damage caused by TMZ; or decreased PARP1 trapping potentially eliminating the additional 
cytotoxic effects of PARP-DNA complexes induced by PARP inhibition.  
 
Table 4.1 Drug compounds with differential IC50 values on WT vs SNP cell lines for rs1805407. GI50 values 
derived from NCI60. Statistical significance was assessed with Wilcoxon rank sum test.  
NSC Name FDA status u p 
26271 Cyclophosphamide FDA approved 175 0.01 
157035 Parthenolide FDA approved 148 0.02 
683863 Irofulven (Hydroxymethylacylfulvene) FDA approved 267.5 0.02 
409962 Carmustine FDA approved 294 0.03 
747856 Olaparib FDA approved 342.5 0.64 
 
4.4.4 SNP rs1805407 is related to PARP inhibitor potentiation of alkylating agent 
cytotoxicity 
Experimental validation of the association of a SNP to increased PARP1 activity in patient-
derived tissues is not straightforward because PARP1 is an inducible enzyme and its activity may 
depend on the timing of the biopsy with respect to prior therapies. Alternatively, one can use cell 
lines to test whether PARP1 inhibition affects the response to alkylating agents in an SNP-
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dependent way. This can be done by blocking PARP1 after treatment with an alkylating agent in 
cells with or without the SNP.  
Literature search (performed in conjunction with Irina Abecassis) identified 13 cell lines  
(Table B.2) from various tumor types, which had reported activity of alkylating agents alone or 
in combination with a PARPi (CEP-6800, AG14361, NU1085, NU1025 or ABT-888) (Delaney 
et al. 2000a; Miknyoczki and Jones-Bolin 2003; Tentori et al. 2003; Calabrese et al. 2004a; 
Wang et al. 2012b; Davidson et al. 2013). We used qRT-PCR (experiments preformed by Irina 
Abecassis) to confirm the rs1805407 genotypes in these cell lines. We classified cell lines as 
“resistant” to the combination of TMZ with PARPi if the reported experiments did not show 
potentiation of cytotoxicity of TMZ when a PARPi was added; likewise, cell lines that showed 
significant potentiation of TMZ cytotoxicity with PARPi were classified as “sensitive”. Four of 
Seven cell lines that had at least one C in position rs18050407 were sensitive, and all six cell 
lines that were WT (T/T) were resistant (p=0.01, G test).  
Although these are intriguing observations, the information used in the analysis was 
collected from different labs that used different PARPi to determine sensitivity or resistance. 
Therefore, we performed similar experiments on nine cell lines from various histologies 
(melanoma, lung, colon, ovarian, and breast cancer): five WT (T/T) and four C/T for SNP 
rs1805407 (Table B.3). MMS was used as alkylating agent and ABT-888 was used to inhibit 
PARP activity. All four SNP cell lines were found to be significantly more sensitive to the 
combination treatment in agreement with our hypothesis; while in all five WT cell lines the 
combination treatment had no potentiation effect (Figure 4.2a). Notably, for the WT cell line 
SW620 ABT-888 significantly increased the IC50 of MMS suggesting potential antagonism 
(experiments performed by Irina Abecassis).   
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a b  
Figure 4.2 PARP1/SNP genotype is predictive of MMS+PARPi combination treatment efficacy. Plot of the IC50 
values. a. ABT-888; and b. olaparib treatment. MMS: alkylating agent used; ABT-888 or olaparib: PARP1 inhibitor 
used; left bars: MMS only; right bars: MMS+PARPi. Dark grey bars: wild type (T/T) for rs1805407; light grey 
bars: heterozygotes (C/T). Star indicates that combination treatment (MMS+PARPi) has significantly different 
effect than alkylating agent alone (p<0.05, Student’s t-test, paired two-tailed).  
 
We extended those results to olaparib treatment of A2780 (SNP) and SW620 (WT) cell 
lines and observed similarly significant potentiation of MMS cytotoxicity with the addition of 
olaparib in A2780 and no potentiation in the SW620 cells (Figure 4.2b). We note that the 
potentiation factor in A2780 cells increased from 2.35 with ABT-888 (10 nM) to 4.65 with 
olaparib (5 nM) (Table B.3). 
4.4.5 PARP inhibitors and alkylating agents exhibit synergy in relation to SNP rs1805407 
and antagonism in relation to the wild-type genotype 
We investigated the potential combinatorial effects of alkylating agent (MMS) and PARPi 
(ABT-888) on cell lines with different rs1805407 genotypes. Exponentially dividing cells were 
73 
exposed for 72h to increasing concentrations of ABT-888 (0-500 µM) or MMS (0-1 mM) alone 
(single drug treatment) or combined at a fixed ratio based on their corresponding IC50 value 
(drug combination treatment). Cell survival was assessed by MTT assay. We then determined the 
Chou-Talalay combination index (C.I.) (Chou and Talalay 1984) of ABT-888 with MMS in four 
established cell lines: two with the variant C/T (A2780-ovarian cancer and M14-melanoma) and 
two WT T/T (SW620-colon and H522-lung cancer). Although C.I. is not a statistical measure, it 
nevertheless provides insight into whether the effect of both agents is additive (C.I.=1), 
synergistic (C.I.<1), or antagonistic (C.I.>1). Both cell lines with the SNP variant exhibited 
synergy (strong and moderate effect in A2780 and M14, respectively; Table 4.2). In WT cell 
lines the effect is additive at best (H522). Interestingly, the SW620 cell line had decreased MMS 
cytotoxicity after the addition of ABT-888. This might indicate antagonism as the C.I. was 
substantially higher than 1.   
 
Table 4.2 ABT-888/MMS combination indices (C.I.-ED50) in WT vs PARP SNP rs1805407 carrier cell lines. C.I.-
ED50 values (mean ± SD) are indicated. For each cell line, equipotency ratios were calculated from the IC50 of 
MMS and ABT-888 used as single agent by MTT assay as outlined in the Methods section. Data from n≥3 
independent experiments was used to calculate the Combination Index (C.I.) with the Compusyn program according 
to the method of Chou and Talalay. A C.I. < 1, = 1, and >1 is indicative of synergism, additivity and antagonism, 
respectively. ED50 is defined as the median effective dose.  
Cell line  PARP1/SNP genotype  Combination ratio  C.I.-ED50  Interpretation  
A2780  C/T 3.8:1 0.18 (± 0.04)  strong synergy  
M14  C/T 2.3:1 0.74 (± 0.08)  moderate synergy  
H522  T/T 2.0:1 1.26 (± 0.26)  slight antagonism/additivity  
SW620  T/T 1.2:1 1.41 (± 0.08)  moderate antagonism  
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4.4.6 SNP rs1805407 is linked to higher expression of PARP1-003 splicing variant 
So far, we have established that PARP1 SNP rs1805407 is directly linked to worse response to 
alkylating therapy in metastatic melanoma patients and in combination treatment of cell lines. 
Furthermore, we have shown that there is a synergistic effect of alkylating agent MMS and ABT-
888 in cell lines with the SNP. However, we do not have a plausible molecular mechanism for 
this phenomenon.  Analysis of our melanoma cohort and the TCGA melanoma data showed that 
PARP1 expression does not increase significantly in metastatic versus non-metastatic patients 
(data not shown). According to Ensembl, however, there are ten PARP-1 alternatively spliced 
transcript isoforms, four of which are protein coding: the predominant form, PARP1-001, and 
PARP1-003, PARP1-005 and PARP1-201. In the predominant form of PARP1 transcript, SNP 
rs1805407 is located 35 bases downstream of the end of exon 2 and it is in perfect LD with SNP 
rs1805405, which is s located 5 bp upstream from the intron 2/exon 3 splice junction and is 
annotated as ‘Splice region variant’. PARP1-003 (ENST00000366790) misses the splice site at 
the end of exon 2/exon-3 (chr1:226,590,083; hg19) and continues translating another 59 amino 
acids before it reaches a stop codon (Figure 4.3). Thus the resulting protein, PARP1-003, is 
short (155 amino acids instead of 1,014) and contains only the first of the two zinc finger 
domains (ZF1) and none of the two catalytic PARP1 domains (Eustermann et al. 2011). It is 
known that ZF1 plays a role both in recognition and DNA binding and PARP catalytic activity 
(Ikejima et al. 1990; Mortusewicz et al. 2007; Altmeyer et al. 2009), but its overexpression leads 
to inhibition of alkylation-induced DNA repair in mammalian cells (Molinete et al. 1993). 
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Figure 4.3 Genomic structure of the fist exons of PARP1 main transcript (PARP1-001) and its truncated 
alternatively spliced form (PARP1-003). This variant is found to be increased in patients with at least one rs1805407 
minor allele. 
 
To further study the potential role of rs1805407 in the function of PARP1, we calculated 
the abundances of the various PARP1 isoforms in 418 TCGA ovarian cancer patients (Level 2 
data) and compared these abundances between groups of patients with and without rs1805407. 
We found a strong association between rs1805407 and the abundance of the PARP1-003 
isoform. Carriers of at least one variant allele (N = 132) have small but statistically significantly 
higher ratio of PARP1-003 abundance to PARP1-001 abundance compared to non-carriers 
(N=286) (p = 4e-08, Mann Whitney U test). This ratio ranges from 0.11% for non-carriers to 
0.32% for SNP homozygotes. Similar, but less significant, results were observed in the 293 
TCGA metastatic melanoma patients (data not shown). 
Finally, we performed quantitative PCR (qRT-PCR) on three cell lines (T/T: H522, 
SW620; C/T: A2780) with primers specific for the full length PARP1 (PARP1-001) and PARP1-
003 (experiments performed by Maria Kapetanaki). The qRT-PCR was performed on RNA 
collected before and after treatment with either DMSO as control or ABT-888.  We found that 
the expression of both isoforms in A2780 cells is significantly higher than in WT cells. Also, 
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ABT-888 significantly inhibits PARP1-003 mRNA expression, while it has no effect on full 
length PARP1. However, PARP1-003 downregulation in WT cells is more profound than in SNP 
cells (74% and 69% for H522 and SW620, respectively compared to 38% for A2780). This result 
shows a trend that is consistent with the theory that SNP carrier cells have increased expression 
of the short, ZF1 containing PARP1-003 isoform, which makes them more sensitive to a 
combination therapy as its overexpression leads to inhibition of alkylation-induced DNA repair 
(Molinete et al. 1993) and catalytic inhibition of PARP leads to PARP trapping (Hopkins et al. 
2015). 
4.5 DISCUSSION 
Application of different therapies in well-defined subgroups of patients is the holy grail of cancer 
precision medicine. Using MGM-PCS, a new method for learning probabilistic graphical models 
over multi-modal biomedical and clinical data (Sedgewick et al, in preparation), we discovered a 
novel biomarker (PARP1 SNP rs1805407) that can be used to identify patients who respond 
poorly to chemotherapy and potentially more favorably to PARP inhibition. SNP rs1805407 has 
relatively high prevalence (24-32% and 65.5% in European and African populations, 
respectively). Adequately powered future validation studies will test the clinical application of 
this SNP as a response biomarker. 
PARP1 acts as a “molecular sensor” to identify DNA single strand breaks. It is then 
recruited and activated as a homodimer in a fast reaction which is amplified 10 to 500-fold with 
formation of poly-(ADP-ribose) (PAR) polymers within 15-30 seconds. Upon binding to a 
damaged strand via its zinc finger DNA-binding domains, PARP-1 undergoes a conformational 
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change inducing the C-terminal catalytic domain to transfer ADP-ribose moieties to protein 
acceptors, including the central auto-modification domain of PARP1 itself. AutoPARylation of 
PARP1 and PARylation of chromatin proteins promote the recruitment of DNA repair factors 
(Masson et al. 1998; El-Khamisy et al. 2003; Schreiber et al. 2006). Extensive autoPARylation 
of PARP1 results in dissociation from DNA, which is required for DNA repair completion 
(Satoh and Lindahl 1992).  The impact of PARP inhibition is more profound than simple 
inhibition of catalysis. For instance, wild-type cells are more sensitive to a PARPi combined with 
the alkylating agent MMS than Parp1−/− mouse cells (Horton et al. 2005; Heacock et al. 2010; 
Kedar et al. 2012).  Furthermore, PARP inhibition delays DNA repair to a greater extent than 
PARP depletion (Strom et al. 2011).  To explain these results, a PARP1-trapping model has been 
proposed (Helleday 2011; Kedar et al. 2012).  This model is based on the idea that PARP1 is 
trapped on DNA by PARPi’s since the automodification and PAR synthesis electrostatically 
destabilizes the PAPR1-DNA complex and lead to rapid dissociation.  PARPi’s therefore 
stabilize PARP-DNA complexes, which are themselves cytotoxic and may underlie the 
differential efficacy of clinically relevant PARPi’s, which differ markedly in their PARP 
trapping potency (Murai et al. 2014a). 
Based on our findings we postulated that SNP rs1805407 affects PARP1 activity during 
treatment with alkylating agents. We found that SNP cell lines were sensitive to combination 
therapy, while WT in general were not. We repeated these experiments with the FDA approved 
PARPi olaparib in A2780 SNP carrier cells and the results were consistent and perhaps more 
profound than with ABT-888. Furthermore, we showed that in SNP cell lines the combination 
treatment was synergistic, while in WT cell lines was at best additive or even antagonistic.  We 
also note that this effect is independent of BRCA1 mutation since none of the tested cell lines 
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carried this mutation. These are very important results as SNP rs1805407 can be potentially used 
in the future to decide whether a patient will receive a combination therapy or not.  
Next, we investigated potential molecular mechanisms that can explain these data. SNP 
rs1805407, located in the beginning of intron-2, is in perfect LD with rs1805405, which is 
located just 5 bp upstream of the intron-2/exon-3 splice junction.  We investigated whether 
rs1805407 is signifying an increase in expression of PARP1-003, an alternatively spliced 
isoform that codes for a shortened protein that includes only exons 1 and 2, thus coding only for 
the first zinc finger (ZF1) of PARP1. In PARP1 protein, ZF1 is responsible for recognition of 
DNA lesions and for initiation of DNA repair (Ikejima et al. 1990; Mortusewicz et al. 2007; 
Altmeyer et al. 2009). However, its overexpression can lead to inhibition of DNA repair 
(Molinete et al. 1993). Also, the short isoform uniquely maintains the auto-modification domain, 
which is most critical to PARP trapping 
By analyzing the TCGA RNA-seq melanoma data we discovered that patients with one 
or two alleles of rs1805407 have significantly increased relative abundance of isoform PARP1-
003 vs PARP1-001 (the full length mRNA), but the difference was small in absolute numbers. 
We should note, however, that. TCGA data are generated from pre-treatment samples, generally 
from primary tumors, and in melanoma predominantly from metastatic sites. PARP1 expression 
is accelerated at the time of DNA damage. The presence of SNP rs1805405 may affect the 
splicing rates and relative abundances of PARP1 isoforms, thus altering their relative protein 
levels. This is relevant in patients, especially knowing that TMZ is utilized in regimens that span 
either 5 days or 21 days out of 28-day cycles. Further experiments in a clinical setting are 
required to determine whether this hypothesis is true.  
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We performed qRT-PCR to measure expression of PARP1-001 and PARP1-003 before 
after ABT-888 treatment. While qRT-PCR results can not measure relative abundance of 
PARP1-001 and PARP1-003, they showed that SNP carrier A2780 cells have higher baseline 
expression of PARP1-003 than WT cells. Our analysis identified two SNPs in the 
PARP1proximal promoter, which are in perfect LD with rs1805407, and overlap peaks of many 
cancer-related transcription factors. These may account for the differences in baseline abundance 
of both isoforms in SNP vs WT cells. 
qRT-PCR also showed that ABT-888 downregulates PARP1-003 mRNA levels 
significantly in WT cells, while reduction in A2780 cells is modest. When a PARPi is utilized, 
then full length protein PARP can bind to the DNA lesion, but not initiate catalysis. Therefore, it 
becomes non-functional and trapped.  This occurs on WT and SNP carriers at similar rates. 
However, SNP cells express significantly more PARP1-003 than WT cells, and PARP trapping 
will occur at a higher rate in the presence of more PARP1-003, resulting in increased 
cytotoxicity and synergism of PARPi with chemotherapy in cells with the variant SNP. In WT 
cells, the levels of PARP1-003 are likely not high enough to have a noticeable effect on 
cytotoxicity as our results show. Our findings were validated in cancer cell lines from various 
histologic subtypes indicating their relevance to the underlying biology of PARP inhibition; and 
are most remarkable in ovarian cancer for which the PARP inhibitor olaparib is FDA-approved. 
Taken together, we postulate that SNP rs1805405 causes increased expression of both 
PARP1-001 and PARP1-003 in patients with one or two variant alleles.  Higher baseline PARP1 
expression may explain the resistant phenotype in patients in the absence of a PARPi, since 
higher expression of PARP1 is correlated with worse outcome (Goncalves et al. 2011). PARP 
trapping is not relevant in this case, since PARP1-001 is expressed at much higher level than 
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PARP1-003 (TCGA pre-treatment results), and a small fraction of PARP1-003 does not mitigate 
the resistant phenotype observed. However, PARP1-003 expression becomes important when 
PARPi is used, as the PARP1-001 will be trapped on the DNA and PARP1-003 may augment 
this trapping. In summary, this study identified PARP1 SNP rs1805405 as a key biomarker for 
stratification of cancer patients in combination therapy (chemotherapy + PARP inhibition). We 
did so by applying a new computational approach for data integration and analysis to a cohort of 
metastatic melanoma patients. We validated, in vitro, the biologic impact of rs1805407 on the 
outcome of PARP1 inhibition in combination with alkylating agents and generated testable 
hypotheses that will further solidify its role in patient selection.  The potential limitations of the 
paper and future directions are twofold. One is that the current manuscript contains mostly in 
vitro confirmation of our findings from our melanoma patient cohort and TCGA data for 
melanoma and ovarian cancer. We plan to apply this methodology on prospective clinical trials 
that have been conducted with PARP inhibitors. Second, the details of the potential mechanism 
of action of this SNP need further investigation.  
The accurate prediction of therapy outcomes based on the molecular characteristics of 
tumors may alter the current landscape of cancer therapy given that immunotherapy results in 
substantial objective responses only in subsets of patients. One can therefore expect that the 
accurate patient stratification into therapy-response categories may allow the overall percentage 
of disease control to soar utilizing the current therapeutic armamentarium. In addition, insights 
into the molecular mechanism that characterizes a therapy-resistant phenotype may usher in new 
strategies to overcome therapy resistance. 
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5.0  PATHWAY BASED DATA INTEGRATION 
Up until this point, this dissertation has focused on de novo network reconstruction methods that 
attempt to learn a network from a given dataset without any prior knowledge of the relationships 
between the variables. Essentially, we have been fitting a network structure to the data. We have 
drawn from the large amount of available biological knowledge to validate the network 
predictions generated by these methods, but not to learn the networks themselves. In this chapter 
we will present new work on a well established method that comes from the opposite direction in 
that it relies on a network structure curated from biological data and fits the data to this network. 
The algorithm we work with here, PARADIGM(Vaske et al. 2010; Sedgewick et al. 2013), also 
fits with the overall theme of this dissertation in that it is designed to integrate multiple data 
sources in order to accurately model the protein and pathway activity in the cell. PARADIGM is 
a popular algorithm for studying cancer data and is well established for its ability to integrate 
genome-wide DNA copy number and mRNA data. In addition since PARADIGM constructs its 
network from user defined “dogmas” (as in the central dogma of molecular biology) and network 
knowledge files, it is in principal easy to extend to more data types. In this chapter we will 
describe our work on adding another data type commonly used in cancer research, microRNA 
(miRNA) to the PARADIGM model. Our new model is able to recover miRNA markers in 
breast cancer tumors that are well established in the literature, which suggests that it will also be 
useful for detecting new miRNA markers to assist with diagnosis and treatment of cancer. 
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5.1 CHAPTER SUMMARY 
MicroRNAs play an important role in regulation of gene expression, and are known biomarkers 
for breast cancer as well as other malignancies. PARADIGM is a pathway based algorithm that 
allows for integration of multiple genomic data types with a curated pathway database to make 
pathway activity predictions. We added a model of gene silencing due to miRNA to the 
PARADIGM algorithm in order to study miRNA expression in a pathway context. We curated a 
set of 7751 miRNA-mRNA interactions from the union of 3 target prediction algorithms. These 
interactions involved 66 miRNA and 2814 mRNA transcripts. We ran our model on copy 
number, RNAseq and miRNAseq data from 697 patients in the TCGA breast cancer cohort, and 
studied changes in the learned interactions between active miRNAs and their targets between 
different subtypes. The miRNA-target pairs with the largest correlation changes between Basal 
and Luminal A subtypes were enriched for known oncogenes, and for miRNAs and genes related 
to the activity of miRNAs in cancer. In addition these targets are involved in a number of 
relevant signaling pathways including PI3K-AKT, JAK-STAT, RAP1 and RAS. Most of these 
highly differential links involved the miR-16 family of miRNAs which are known tumor 
suppressors. Two miRNA-mRNA target pairs showed the largest changes in link strength of any 
pathway links between Basal and Luminal A groups. The miRNAs in these pairs, miR-195 and 
miR-221, are both previously documented markers in breast cancer. By looking at changes in 
miRNA-target links between tumor subtypes, our extension to PARADIGM allowed us to 
identify both miRNAs and target genes involved in pathways relevant to breast cancer. 
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5.2 BACKGROUND 
MicroRNA, or miRNA, are short (18-25 nucleotide) non-coding RNA molecules that target 
mRNA transcripts and silence genes via a variety of mechanisms. Gene silencing due to miRNA 
targeting plays a part in many biological processes, and miRNA target sequences have been 
predicted in as many as 30% of genes (Lewis et al. 2005). Dysregulation of miRNAs has been 
linked to a variety of human diseases including pulmonary fibrosis (Pandit et al. 2010), and 
atherosclerosis (Toba et al. 2014). miRNAs have been studied extensively in cancer, and many 
reviews of their role are available (Melo and Esteller 2011; Jansson and Lund 2012; Malumbres 
2013; Ohtsuka et al. 2015). In order to post-transcriptionally silence genes, miRNAs associate 
with several proteins to form an RNA Induced Silencing Complex (RISC) that carries out the 
biological process that leads to silencing. While the membership of RISC can vary depending on 
the organism and context, the minimal component proteins in humans are the RNAase Dicer, 
which processes the miRNA transcripts into a mature form, the Argonaute family of proteins, the 
catalytic component of RISC, and TRBP, which recruits the Argonaute proteins to Dicer and the 
bound miRNA molecule (Chendrimada et al. 2005). 
A key challenge for working with miRNA that is applicable to this study is how to 
identify the mRNA targeted by each miRNA. Due to the difficulty of experimental verification 
of miRNA-mRNA targeting, there are relatively few validated targets. Instead, a variety of 
methods exist to predict targeting based on factors such as sequence, binding energy and 
conservation. Often the amount of overlap between these various methods is low relative to the 
number of predicted targets, so a common approach is to use the union of several of these 
methods to find a set of high-confidence target predictions (Huang et al. 2011; Coronnello and 
Benos 2013). We follow the approach of mirConnX (Huang et al. 2011), and use the union of 3 
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popular methods: TargetScan (Friedman et al. 2009), miRanda (Enright et al. 2004), and PicTar 
(Krek et al. 2005). 
A number of previous studies have attempted to combine miRNA target predictions with 
either pathway data (Lu et al. 2012), mRNA expression (Zhang et al. 2014), or both (Huang et al. 
2011). MirSystem (Lu et al. 2012) links miRNA to pathway knowledge via their mRNA targets, 
and performs enrichment tests to determine which pathways are likely to be regulated by a given 
group of miRNAs. Zhang et al (Zhang et al. 2014) use causal learning methods combined with 
matched miRNA and mRNA data to predict miRNA activity in a condition specific manner. 
MirConnX (Huang et al. 2011) combines matched miRNA and mRNA data with target 
predictions and transcription factor regulation data to find condition specific regulatory 
networks. PARADIGM offers several advantages over these methods. First, while a number of 
these methods offer condition specific models, PARADIGM is able model patient-specific 
pathway activities, which allow for more flexible downstream analyses. In addition  these 
methods study paired miRNA and mRNA data by looking at pairwise correlations between the 
miRNA-target pairs, while PARADIGM allows us to study these interactions using predictions 
of active miRNA silencing complexes. Thus, if proteins essential to the silencing pathway such 
as Argonaute or DICER are not active in the sample, PARADIGM will predict less miRNA 
regulation in that sample. 
PARADIGM builds a factor graph out of a curated database of pathways in order to infer 
the unobserved levels of activity of individual proteins, protein complexes and families from 
observed DNA and mRNA data. The observed data is discretized to three levels corresponding to 
high, low and normal. For every protein in the PARADIGM pathway, a model of the central 
dogma of molecular biology (see Figure 5.1) is included in the factor graph. Each step in the 
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dogma has an unobserved node in the graph: DNA, RNA, protein, and active (for activated 
protein). Each of these latent nodes is linked to observed data, if available, and to the active 
nodes of other genes that are annotated as regulators in the pathway database. The states of the 
latent nodes are then inferred from the data using loopy-belief propagation to perform 
Expectation-Maximization. 
Although the relationships between the variables in PARADIGM are set, the parameters 
of the factors, which model the relationships between the nodes they connect, are learned by the 
algorithm. In our previous work with PARADIGM (Sedgewick et al. 2013), we added a model of 
regulation that allows the algorithm to learn parameters that describe the regulatory relationship 
between active proteins and the transcription, translation, or activation of the proteins that they 
regulate. So, although it is not possible to learn new edges with PARADIGM, by looking at the 
regulation parameters learned from the observed data, we can measure how strong edge is in a 
given set of samples.  
5.3 METHODS 
5.3.1 Pathway Model 
miRNA is included in the PARADIGM model using the same dogma that coding RNAs use. The 
only dogma node that doesn’t apply to miRNA is the protein node, and since there are not 
translational or activation regulators for the miRNA in our pathway, the active node will have the 





Figure 5.1 a Minimal RNA Induced Silencing Complex model, separated for transcriptional (TX) and translational 
(TL) regulation. b Model of how the active RISC-miRNA complexes interact with a protein dogma model. 
Our RISC model uses the built-in complex model in PARADIGM, which is a “noisy 
AND” function. In other words, the predicted activity state of the complex is the minimum of the 
states of all the components of the complex with high probability, or another state with small 
error probabilities. Figure 5.1a shows our RISC model, which is separated by the putative 
regulation mechanisms of the different proteins in the Argonaute family. Argonaute 2 (AGO2) is 
part of a complex that regulates transcription because of its endoribunuclease activity that allows 
it to cleave mRNA molecules thereby silencing them (Kobayashi and Tomari 2016). Although 
this process happens post-transcription, kinetic studies of cleavage by AGO2 suggest that it 
happens rapidly enough that it will affect observed mRNA transcript levels (Ameres et al. 2007). 
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We treat the rest of the Argonaute family as translational regulators because their alternative 
silencing mechanisms are less likely to affect the observed mRNA transcript levels. These 
mechanisms include translation regulation activity such as direct translational repression via 
recruitment of additional factors and deadenylation of the poly(A) tail of the mRNA molecule, 
which in turn inhibits translation (Kobayashi and Tomari 2016). These different regulation 
models interact with the regulation nodes of a predicted target protein as shown in Figure 5.1b.  
We compare 2 models in this study: the full model with both transcriptional and 
translational repression by RISC as presented in Figure 5.1b, and a simpler model that only adds 
the transcriptional regulation component corresponding to mRNA cleavage by AGO2. We work 
with the simpler model in case the full model gives too much weight to miRNA silencing. Given 
that  without miRNA silencing there are 11,120 regulatory interactions in the pathway, none of 
which are translational regulators, it seems possible that adding 7,751 miRNA interactions as 
both transcriptional and translational repressors may drown out the signal of the rest of the 
pathway. 
5.3.2 miRNA Target Predictions 
We use intersection of miRNA-mRNA target predictions from 3 miRNA target prediction 
algorithms: TargetScan (Enright et al. 2004), miRANDA (Friedman et al. 2009), and Pictar 
(Krek et al. 2005). This database of targets comes from mirConnX (Huang et al. 2011). This 
procedure generated 7751 miRNA-mRNA interactions involving 66 miRNA and 2814 mRNA 
transcripts. 
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5.3.3 TCGA Breast Cancer 
We used matched RNAseq, miRNAseq and DNA copy number data for 697 patients from the 
TCGA Breast Cancer Cohort. For the DNA copy number data we used GISTIC 2.0 predictions 
(Center 2016). To normalize the RNAseq data, we removed transcripts with zero reads in  more 
than 50% of samples, log-scaled TPM values and median normalized each transcript across all 
samples. For miRNA normalization we filtered miRNAs with zeros reads in more than 75% of 
samples then log scaled the raw counts and median normalized each miRNA across all samples. 
For validation of our PARADIGM model, we also use Reverse Phase Protein Array 
(RPPA), hormone receptor status from immunohistochemistry, survival and PAM50 subtype 
predictions for these patients. 
5.3.4 PARADIGM Application Tests 
To score how well a learned PARADIGM model matches the underlying biology of a sample, 
we use a battery of previously developed application tests. One test compares the pathway 
activities of the Estrogen Receptor gene ESR1 as well as the dimer ER! to the ER status 
determined by immunohistochemistry (IHC). Similarly, HER2 status from IHC is compared to 
the predicted activity of the corresponding gene, ERBB2. For another validation test, we 
compare protein data from RPPA to the PARADIGM predicted protein activities. A new test 
added in this study looks at the correlation of pathway activities of PLK1 and one of its 
transcriptional regulators, FOXM1. PLK1 is a hub in the PARADIGM network and involved in 
several feedback loops, one of which involves FOXM1, and we have found that a strong 
correlation between these closely linked genes is indicative of a good model fit. 
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Another dimension of testing is survival prediction. For this test, we filter out censored 
patients (i.e. alive at last checkup) and split the cohort of patients in to quartiles based on 
survival times. The top 25% of patients with the longest survival times are treated as the positive 
class, and the bottom 25% are used as the negative class. We performed this experiment on both 
the whole breast cancer cohort (15 patients of each class) and only the estrogen receptor positive 
(ER+) patients (9 patients of each class. We fit a linear SVM (from scikit-learn: http://scikit-
learn.org/stable/index.html) on these labels (positive samples labeled as +1, negative as -1) using 
the Integrated Pathway Activities (IPA) produced by PARADIGM. We measure the 
classification accuracy using leave one out cross-validation. 
5.3.5 Functional Enrichment 
To asses the biological relevance of groups of genes we use standard gene set enrichment 
analysis methodology to test which pathways or gene annotations are over-represented in our set 
of genes. Specifically we use the ‘kegga’ and ‘goana’ functions built into the R package, limma 
(Ritchie et al. 2015). 
5.4 RESULTS AND DISCUSSION 
5.4.1 Distribution of miRNA-target Links 
We compared the distributions of the PARADIGM link parameter correlations for models 
learned with both the transcription only model (Figure 5.1a), and the full model (Figure 5.1b). 
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Correlations are calculated from the parameters (which are essentially conditional probability 
tables, CPTs, see (Sedgewick et al. 2013) for more detail) that connect the “active” node of the 
regulating protein to one of the “regulation” nodes (either transcriptional, translation, or protein 
activation as shown in Figure 5.1b). The distributions of the different types of regulatory links 
are essentially the same between the models other than the additional miRNA translation 
regulation links added in the full model. This indicates that the translation links don’t seem to 
have a noticeable affect on other links in the pathway.  
All links are started from the same set of initial parameters which are either positive or 
negatively correlated based on whether the link is annotated as activation or inhibition in the 
pathway (specifically, a probability of .8 on the diagonal of the CPT and .1 off the diagonal). 
From Figure 5.2 we can see that the miRNA translation regulation links do not seem to stray 
very far from the initial inhibition parameter setting, while the other link types spread nicely to 
match the data, with links not supported by the data drifting towards 0 and links that are 
consistent with the data spreading towards the positive and negative extremes. Possible 
explanations for this lack of learning include the fact  
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Figure 5.2 Density plots of Pearson’s correlation of regulation links from parameters learned with PARADIGM 
































that these links are the only translational regulation links in the pathway, so they are not balanced 
by any activating translational regulation links, and secondly, the translation regulation nodes 
may be receiving less signal from the data because of their spot on the pathway between the 
mRNA node which is directly linked to the observed data and the protein node which is not. 
Activation regulation links are similarly positioned some distance from the data nodes in the 
pathway, but they seem to better able to conform to the data, perhaps because of the connections 
of the active nodes to the regulation nodes of other proteins and complexes. 
5.4.2 Survival Prediction 
To see how well the Integrated Pathway Activities (IPAs) predicted by the different 
PARADIGM models represent the underlying biology of the tumors, we studied how well they 
are able to predict patient survival. We treat this task as a classification problem where the two 
classes are patients in the top quartile or the bottom quartile of survivals. Due to incomplete 
survival data for many patients, this left us with a set of 30 patients, 15 high survival and 15 low 
survival. The miRNA transcription regulation model performed the best, an SVM trained on 
IPAs from this model achieved a leave-one-out cross validation accuracy of 60% while the full 
model achieved poor accuracy of 43%, as did a model learned without any miRNA data, 37% 
accuracy. The performance of the simpler model is comparable to doing the classification with 
RNAseq data (59% accuracy) or RNAseq and miRNAseq data together (62% accuracy). 
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5.4.3 Correlation of IPAs with Protein and IHC Data 
Another method for validating our models is to compare to other data types. We compare the 
IPAs from each model for ESR1 and the ER! homodimer to compare to estrogen receptor status 
as measured by IHC, and for ERBB2 to compare to IHC measured HER2 status. The IHC 
experiment gives a call of positive or negative for each hormone receptor, so we performed a two 
sample ranksum test of the IPAs for the positive versus negative groups of the corresponding 
hormone receptor. All three models performed well on these tests. The full miRNA model had 
highly significant p-values from the tests: 2.9e-48 for ESR1, 2.9e-47 for the ER! homodimer, 
and 1.2e-9 for ERBB2. The transcription-only miRNA model has slightly lower p-values: 1.4e-
49 for ESR1, 7.9e-48 for ER! homodimer, and 2.8e-11 for ERBB2. The original PARADIGM 
model without any miRNA data had the lowest p-values for ESR1 (8.5e-50) and ERBB2 (9.1e-
12), but the highest for ER! homodimer (9e-46). 
We compared the IPAs from each model to protein concentrations from 173 proteins in 
the TCGA breast cancer samples measured with RPPA. For each protein we measured the 
correlation of the RPPA data with the IPAs across all patients with RPPA measurements. We 
then averaged these correlations. There was no separation between the 3 models for this test. All 
three models had an average of Spearman correlations of .24 between the RPPA and IPAs with 
standard errors between .017 and .018. This result is somewhat surprising since 45 of the 173 
proteins found in the RPPA data are targets of the miRNAs that we added to PARADIGM. It is 
possible, however, that these proteins are strongly regulated in the original PARADIGM network 
so that adding miRNA did not alter their IPAs noticeably. 
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5.4.4 Top miRNA-target Links 
Although the battery of tests in the previous section does not clearly separate either of the 
miRNA regulation models, we now choose to focus on the links learned by the transcription-only 
model because it performed better in all tests and because Figure 5.2 shows that the transcription 
regulation links are likely to have more informative parameters. In this section we investigate 
how our miRNA-target links change between breast cancer subtypes, specifically we compare 
the 97 patients with the aggressive basal tumors to 288 patients with more treatable luminal A 
tumors. 
We sorted miRNA-target links by the largest change in correlation between the basal and 
luminal A subgroups. Of the top 10 links with large correlation changes between the groups, 9 of 
them involve miR-16. This is likely due to the very low IPA of miR-16 in basal tumors (median -
4.0) compared to luminal A tumors (median 0) (Wilcoxon p < 2e-16). miR-16 is a known tumor 
suppressor that has been characterized in a variety of cancers including lymphoma, leukemia and 
breast cancer (Aqeilan et al. 2010; Rivas et al. 2012). The targets of the top 200 links by 
correlation change are significantly enriched (false discovery rate < .05) for a number of 
pathways relevant to cancer, shown in Table 5.1. While the majority of these pathways are 
cancer related, the fact the we recovered the “MicroRNAs in cancer” pathway as an enrichment 






Table 5.1 KEGG enrichment for the gene targets of the top 200 miRNA-target links by correlation change between 
basal and luminal A breast cancer subgroups. 
Pathway Pathway Size Number Found FDR 
Jak-STAT signaling pathway 32 8 3.499e-06 
Rap1 signaling pathway 70 10 1.506e-05 
PI3K-Akt signaling pathway 95 9 2.470e-03 
MicroRNAs in cancer 78 8 4.457e-03 
Melanoma 23 5 4.649e-03 
Pathways in cancer 132 10 5.570e-03 
Focal adhesion 65 7 1.121e-02 
Regulation of actin cytoskeleton 67 7 1.362e-02 
Endocytosis 70 7 1.806e-02 
Ras signaling pathway 73 7 2.360e-02 
HTLV-I infection 73 7 2.360e-02 
Proteoglycans in cancer 73 7 2.360e-02 
Wnt signaling pathway 55 6 3.732e-02 
Transcriptional misregulation in cancer 57 6 4.546e-02 
 
In addition to correlation, we commonly use a G-test to measure the statistical 
dependence of the variables, which we refer to as link “strength”. The G-test allows us to 
uncover links that are highly dependent, but do not necessarily have a linear relationship that can 
be captured by Pearson’s correlation. Looking at the rank difference of G-test p-values between 
the basal and luminal groups, reveals that two miRNA regulation links have the largest change 
out of all links in the pathway. miR-221-ARF4 shows a strong connection in the luminal A 
subgroup (FDR = 9.9e-7), but a relatively weaker relationship in basal tumors (FDR = 1.5e-3). 
Both nodes in this link have been previously linked to breast cancer: overexpression of miR-221 
is linked to aggressive, basal tumors through promotion of epithelial-to-mesenchymal transition 
(Shah and Calin 2011) and ARF4 expression is linked to cell migration and metastasis in breast 
cancer (Jang et al. 2012). Similarly, miR-195-BDNF has a strong silencing relationship in 
luminal A tumors (FDR = 5.6e-21) that is weaker in basal patients (FDR = 3.2e-3). miR-195 has 
been identified as a potential circulating biomarker to diagnose breast cancer (Heneghan et al. 
2010) and BDNF is a growth factor that has been shown to promote tumor growth and 
proliferation in colon cancer (Yang et al. 2013). 
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5.5 CONCLUSIONS 
By adding miRNAs, miRNA target predictions, and a model of the RNA induced silencing 
complex to PARADIGM, we were able to create a model that can interrogate miRNA induced 
gene silencing in a pathway context. Based on our comparison between a transcription regulation 
only model to a RISC model that regulates genes at both the transcriptional and translational 
level, we find that our model is better able to learn miRNA-target links at the transcriptional 
regulation level. By comparing differential miRNA silencing in tumor subgroups we identified 
miR-221, miR-195 and miR-16 as important regulators in breast cancer. All of these miRNAs 
had been previously studied in breast cancer, and the genes they targeted proved to be enriched 
for cancer related pathways as well. Thus the predictions made by our model had strong support 
in the literature. 
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6.0  CONCLUSIONS AND FUTURE WORK 
In this dissertation, we have presented a variety of network based data integration methods. On 
one end of the spectrum we have developed algorithms that attempt to reconstruct causal 
networks de novo, on the other end, we extended an algorithm for pathway based inference of 
protein activity. We have shown that these types of integrative methods are powerful tools that 
we believe are essential for modern biomedical research. Using our methods we were able to 
identify a prognostic biomarker for response to treatment temozolomide in metastatic melanoma. 
This marker also suggests that a combination treatment strategy that may help treat non-
responders more effectively. In addition, by adding miRNA to PARADIGM, we were able to 
effectively study changes in gene silencing that differentiate more or less aggressive breast 
cancer subtypes. As collecting multimodal data from patient samples becomes the standard of 
care in cancer and other diseases, we expect integrative analyses like ours to continue to assist in 
the understanding, diagnosis and treatment of human disease. 
There are many opportunities for future development of the methods described in this 
thesis. For the MGM described in chapter one, a pressing challenge is to make the learning 
procedure efficient enough to handle genome scale data. This could be achieved by using a 
different optimization algorithm, or by switching to a learning method that uses separate 
regressions rather than optimizing the pseudolikelihood. A model based on separate regression 
would have more flexibility in distributional assumptions and be easy to parallelize. In both 
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MGM and the hybrid MGM-causal search methods, more work needs to be done towards 
encoding prior knowledge in the model. It is simple to force a model to always include or 
exclude edges based on knowledge, but a more nuanced approach is necessary for biological 
pathway knowledge where an edge may only exist in certain cell types under certain conditions. 
Another exciting direction for causal search over mixed data is to develop an efficient scoring 
method to use with score-based causal search methods. Recent work with score based methods 
on continuous data has been promising for application to very large datasets, so a mixed score 
may allow us to take advantage of these new methods. Finally, there are many more data types 
that could be added to the PARADIGM model including DNA methylation, ribosome profiling 
data, and protein measurements. As with miRNA, the challenges for any addition of new data 




PERFORMANCE OF DIRECTED SEARCH ON LOW-DIMENSIONAL DATA 
 
Figure A.2 Precision-Recall curves of edge adjacency recovery for . 05 ≤ ! ≤  .2 and . 001 ≤ ! ≤  .1. and the full 
range of algorithms and edge types. 
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Figure A.2 Precision-Recall curves of edge direction recovery for . 05 ≤ ! ≤  .2 and . 001 ≤ ! ≤  .1. and the full 
range of algorithms and edge types.  
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Figure A.3 Running times of search algorithms on low dimensional data. Directed search steps were run in parallel 











Table A.1 Parameter settings with the best SHD performance by edge type 
in low-dimensional data set 
Algorithm !  ! Type SHD 
PC-Stable 
0.05 none all 95.35 (2.4786)   
0.05 none cc 20.70 (1.6481)   
0.05 none cd 52.45 (1.5139)   
0.05 none dd 22.20 (1.2599)   
MGM-PCS 
0.05 0.071 all 63.25 (2.8385)   
0.1 0.1 cc 11.40 (1.3638)   
0.05 0.071 cd 35.50 (1.9310)   
0.01 0.071 dd 14.75 (1.4343)   
CPC-Stable 
0.1 none all 67.05 (2.7772)   
0.05 none cc 11.20 (1.4190)   
0.1 none cd 39.45 (2.1502)   
0.05 none dd 15.80 (1.3111)   
MGM-CPCS 
0.1 0.14 all 63.35 (2.7513)   
0.1 0.2 cc 10.75 (1.3116)   
0.1 0.14 cd 37.70 (2.0877)   




SUPPLEMENTARY TABLES FOR PARP1 CASE STUDY 
Table B.1 PARP1 SNPs in LD with rs1805407. 
SNP Distance R2 D’ Chr Coord_hg18 GeneVariant 
rs3219031 437 1 1 chr1 224656019 INTRONIC 
rs3219027 580 1 1 chr1 224657036 INTRONIC 
rs6701634 1792 1 1 chr1 224654664 INTRONIC 
rs3754370 2445 1 1 chr1 224658901 INTRONIC 
rs3768347 2912 1 1 chr1 224659368 INTRONIC 
rs3768346 3021 1 1 chr1 224659477 INTRONIC 
rs7522351 3435 1 1 chr1 224659891 INTRONIC 
rs7525191 3438 1 1 chr1 224659894 INTRONIC 
rs4653732 4273 1 1 chr1 224660729 INTRONIC 
rs10799349 4317 1 1 chr1 224652139 INTRONIC 
rs7542788 4530 1 1 chr1 224651926 INTRONIC 
rs7548007 4553 1 1 chr1 224651903 INTRONIC 
rs4653733 4780 1 1 chr1 224661236 INTRONIC 
rs60698376 5024 1 1 chr1 224661480 N/A 
rs4653731 5861 1 1 chr1 224650595 INTRONIC 
rs2077197 6206 1 1 chr1 224662662 UPSTREAM 
rs12240196 6350 1 1 chr1 224650106 INTRONIC 
rs59672299 7760 1 1 chr1 224664216 N/A 
rs1073991 8759 1 1 chr1 224647697 INTRONIC 
rs2136876 8880 1 1 chr1 224647576 INTRONIC 
rs1000033 9446 1 1 chr1 224647010 INTRONIC 
rs6665208 9541 1 1 chr1 224665997 UPSTREAM 
rs1002153 9646 1 1 chr1 224646810 INTRONIC 
rs2280712 9740 1 1 chr1 224646716 INTRONIC 
rs1805405 9812 1 1 chr1 224646644 SPLICE_SITE, INTRONIC 
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rs6679573 11114 1 1 chr1 224667570 INTERGENIC 
rs10915987 11848 1 1 chr1 224668304 INTERGENIC 
rs3219043 12239 1 1 chr1 224644217 INTRONIC 
rs77173384 12382 1 1 chr1 224668838 N/A 
rs28407557 12564 1 1 chr1 224669020 INTERGENIC 
rs4653445 12927 1 1 chr1 224643529 INTRONIC 
rs2293464 13537 1 1 chr1 224642919 INTRONIC 
rs12068460 13912 1 1 chr1 224670368 INTERGENIC 
rs3219053 15279 1 1 chr1 224641177 INTRONIC 
rs1805408 16431 1 1 chr1 224640025 INTRONIC 
rs3219058 17039 1 1 chr1 224639417 INTRONIC 
rs6681537 19603 1 1 chr1 224676059 INTERGENIC 
rs3219073 20458 1 1 chr1 224635998 INTRONIC 
rs2271343 22270 1 1 chr1 224634186 INTRONIC 
rs732284 22825 1 1 chr1 224633631 INTRONIC 
rs3219115 32892 1 1 chr1 224623564 INTRONIC 
rs752308 38327 1 1 chr1 224618129 INTRONIC 
rs747658 38655 1 1 chr1 224617801 INTRONIC 
rs747659 39092 1 1 chr1 224617364 INTRONIC 
rs6664761 39642 1 1 chr1 224616814 INTRONIC 
rs2282400 42834 1 1 chr1 224613622 DOWNSTREAM 
rs6675427 45851 1 1 chr1 224610605 DOWNSTREAM 
rs6675327 45924 1 1 chr1 224610532 DOWNSTREAM 
rs6661762 46142 1 1 chr1 224610314 DOWNSTREAM 
rs1991865 48782 1 1 chr1 224607674 INTERGENIC 
rs12092726 50806 1 1 chr1 224605650 INTERGENIC 
rs3219023 1223 0.947 1 chr1 224657679 INTRONIC 
rs7531668 6186 0.945 1 chr1 224662642 UPSTREAM 
rs12025487 15060 0.945 1 chr1 224671516 INTERGENIC 
rs1109032 28430 0.945 1 chr1 224628026 INTRONIC 
rs3754375 28768 0.945 1 chr1 224627688 INTRONIC 
rs4653735 10521 0.891 1 chr1 224666977 UPSTREAM 
rs878367 52311 0.891 1 chr1 224604145 INTERGENIC 
rs7527192 6246 0.838 1 chr1 224662702 UPSTREAM 
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Table B.2 Potentiation of response to chemotherapy or radiation combined with PARP inhibition (from literature).  
PARP1 SNP rs1805407 genotyping analysis of a panel of human cancer cell lines. All six of the cell lines reported 
in the literature to be "resistant" to chemotherapy + PARPi combination treatment were WT for the rs1805407 locus.  
Four out of the seven cell lines reported to be "sensitive" had at least one copy of C in this locus. Cell line was 
considered "sensitive" when chemopotentiation ratio was ≥ 2. S: sensitive; R: resistant. 






type PARPi agent REFS 
LoVo Colon  R Colon  T/T 
TMZ NU1025/NU1085, 
AG14361 
(Delaney et al. 
2000b; 
Calabrese et al. 
2004b) 
SW620 Colorectal  R Colorectal  T/T Irinotecan ABT-888 (Davidson et al. 2013) 
H522 Lung R Lung T/T TMZ NU1025/NU1085 (Delaney et al. 2000b) 
HT-29 Colon  R Colon  T/T TMZ NU1025/NU1085 (Delaney et al. 2000b) 
SKOV-
3 Ovarian R Ovarian T/T 
TMZ NU1025/NU1085 (Delaney et al. 
2000b) 
LS174T Colon S Colon T/T TMZ NU1025/NU1085 (Delaney et al. 2000b) 
HCT-
116 Colon  S Colon  T/T 
Irinotecan ABT-888 (Davidson et 
al. 2013) 
MDA-
MB-231 Breast  R Breast  T/T 
TMZ  NU1025/NU1085  (Delaney et al. 
2000b) 
MCF-7 Breast S Breast T/T TMZ NU1025/NU1085 (Delaney et al. 2000b) 
Calu-6 Lung S Lung C/T TMZ  CEP-6800 (Miknyoczki et al. 2003) 
M14 Melanoma S Melanoma C/T TMZ 3-aminobenzamide (Tentori et al. 2003) 
A549 Lung S Lung C/T 
TMZ  NU1025/NU1085, 
AG1436 
(Delaney et al. 
2000b; 
Calabrese et al. 
2004b) 







Table B.3 Results from MMS treatment of cell lines with and without PARP1 inhibitor (ABT-888 or olaparib).  The 
data from the MTT assays were expressed as mean ± standard deviation (SD). The ratio between the IC50 means of 
MMS treatment alone and in combination with ABT-888 or olaparib was calculated for each cell line. A 
Potentiation factor (ratio) ≤ 1 indicates no chemo-potentiation. 
ABT-888 (10 nM): 
Cell line Tissue origin 
PARP1/SN
P genotype MMS IC50 (µM) 
MMS + ABT-





FEMX melanoma T/T 166.3 (± 20.2) 176.0 (± 40.4) 0.945 0.626 
A375 melanoma T/T 306.0 (± 22.1) 283.3 (± 33.5) 1.080 0.172 
H-522  lung T/T 577.7 (± 56.8) 745.3 (± 68.6) 0.775 0.147 
SW620  colon T/T 299.4 (± 37.0) 449.4 (± 89.1) 0.666 0.047 
MDA-MB-231  breast T/T 287.2 (± 28.7) 303.2 (± 45.1) 0.947 0.530 
M14  melanoma C/T 520.8 (± 63.4) 359.8 (± 56.7) 1.447 0.005 
A549 lung C/T 254.8 (± 23.9) 143.9 (± 37.8) 1.771 0.002 
A2780 ovarian C/T 190.0 (± 41.0) 80.8 (± 14.7) 2.351 0.003 
H460 lung C/T 227.0 (± 21.4) 134.9 (± 20.5) 1.682 0.002 
Olaparib (5 nM): 
Cell line Tissue origin 
PARP1/SN
P genotype MMS IC50 (µM) 






SW620  colon T/T 342.7 (±68.7) 357 (±55.6) 0.960 0.720 
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